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Blacks have been consistently observed to have higher serum ferritin (SF) 
concentrations than whites; however, few studies have attempted to explore why this 
difference exists. 3,554 non-Hispanic white (NHW) and non-Hispanic black (NHB) male 
subjects, aged 20-65 years, were selected from the third National Health and Nutrition 
Examination Survey (NHANES III) to determine the possible factors that may contribute 
to the observed black-white SF difference. Results of multiple regression analyses 
showed that age, body mass index (BMI), % energy from carbohydrate and fat, calcium 
intake, serum total protein, serum α-carotene, mean cell volume (MCV), iron binding 
capacity (TIBC) and γ glutamyl transferase (GGT) were significantly associated with SF 
concentration. When the final regression model was run after excluding subjects with 
abnormal serum total protein, TIBC and GGT levels, the SF difference dropped to 
3.95µg/L (initial difference=37.06µg/L) between NHWs and NHBs. The results suggest 
that the noted black-white SF difference is a result of factors including overall nutrition 
and health, iron status and hepatic well-being. Higher SF, low Hb and reduced TIBC 
level observed in blacks are consistent with the definition of anemia of chronic disease 
(ACD). Future investigations are needed to confirm the role of ACD in the black-white 
SF difference. 
 We also examined different sub-populations to investigate whether the likelihood and 
magnitude of SF elevation in regard to acute inflammation and hepatitis C are different 
between NHBs and NHWs by using logistic regression analyses. Compared to NHWs, 
NHBs had a 2.239-fold (95% CI, 1.333 to 3.760) greater risk to have elevated SF in 
regard to acute inflammation, and had significantly higher odds ratios of having elevated 
SF per unit change in C-reactive protein (CRP), white blood cell count (WBC), serum 
albumin, lymphocyte and platelet count. However, no significant results were found for 
hepatitis C. The results indicated that NHWs and NHBs had different patterns of iron 
accumulation in regard to acute inflammation. Further elucidation is needed about how 
ferritin regulation is perturbed in diseases, and whether increased stored iron plays a role 
in different clinical outcomes and drug response. Adequately powered studies are needed 
to further investigate the relationship between stored iron and hepatitis C host response. 
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There has been growing research interest in the relationship between excessive iron 
stores and diseases since increased iron store has been proposed to be associated with 
impaired glucose intolerance (1), higher risk of diabetes (2,3), vascular diseases, and 
cancer (4,5). Previous studies have consistently found differences in the hemoglobin and 
serum ferritin concentrations between African Americans (AA) and European Americans 
(EA) (6-8). African Americans have been shown to have higher serum ferritin 
concentrations than European Americans although their hemoglobin concentrations are 
lower. Research attention has been typically focused on finding the explanation to the 
difference in the hemoglobin levels between these two groups whereas the disparities in 
serum ferritin concentrations have been mostly ignored. 
 Recently, Zacharski et al. reported that different patterns of iron accumulation exist 
according to age, sex, and ethnicity based on analysis of NHANES III data (9). Serum 
ferritin levels were compared with the percent transferrin saturation in 20,040 individuals 
> 17 years of age from the third NHANES database. Ferritin levels in non-Hispanic black 
males exceeded those in non-Hispanic whites and Hispanics for each decade of life, and 
differences increased with age. Ferritin levels were comparable for black, white and 
Hispanic women during the premenopausal years. However, after menopause, ferritin 
levels in black women rose more rapidly and exceeded those of white and Hispanic 
women. Overall, they found ferritin levels were approximately 7% to 8% greater for 
blacks than for whites and Hispanics, and differences remained throughout the second 
half of life. 
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In recent years, the issue of the health effects caused by excessive iron stores has 
gained considerable visibility. Since one of the two overarching goals of Healthy People 
2010 is to eliminate health disparities, scientists are now trying to explore the underlying 
biological mechanisms contributing to the higher disease and mortality rates among 
minorities, especially African Americans, Native Americans and Hispanics. Given the 
fact that the greatest health disparities have been consistently observed between blacks 
and whites, most research attention has been focused on finding the explanation for the 
noted differences in disease prevalence, complications, clinical outcomes and treatment 
response between these two groups. 
 Serving as a powerful pro-oxidant, iron plays its role in disease progression by 
catalyzing in oxidation-reduction reaction and causing organ-specific (liver, muscle, and 
pancreas) oxidative damage. Interest in the relationship between different iron 
accumulation patterns with disease distribution has increased in both the scientific and 
public health communities. Several studies have reported that some diseases affect blacks 
disproportionately (10-16). Actually, the death rate from all causes in blacks is 
approximately 1.5 times that of whites. Compared with whites, blacks have worse 
survival after myocardial infarction (10), a 2-fold-higher incidence of and morbidity from 
stroke (11,12), and a higher risk of infrarenal peripheral vascular disease (13). Morbidity 
and mortality rates from diabetes (14), AIDS (15), and cancer (16) are also significantly 
higher for blacks than for whites. Although the higher disease rates in blacks is most 
likely the result of a complex interplay of individual attributes, minority and 
socioeconomic stress and environmental characteristics, several researchers proposed the 
hypothesis that the differences in iron stores may contribute to the disease differences 
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between blacks and whites, especially for type 2 diabetes mellitus, cardiovascular 
diseases and cancer (17-21). The implication of a relationship between excessive iron 
stores and higher disease frequencies among blacks may be one of the reasons for the 
continued findings of health disparities between blacks and whites. But in order to further 
test this “iron hypothesis,” the question of why there is a difference in iron stores between 
blacks and whites, and what are the potential factors contributing to this difference needs 
to be investigated first. Serum ferritin, the most commonly used indicator of total body 
iron stores, hence becomes the focal point for the investigation of iron store disparities. 
Therefore, the primary goal of our study is to determine the possible factors which 
contribute to serum ferritin difference between blacks and whites by using national 
representative data.  
Genetic variance is often cited as a possible reason for differences in diseases and iron 
status between blacks and whites. Consistently found higher disease rates and lower 
hemoglobin concentrations among blacks than among whites are often misleadingly 
explained by “race.” The chief argument against the notion is that biological race 
sometimes can be medically meaningless because genetic polymorphisms are more 
variable within-ethnicity than between-ethnicity. Although genetic factors may play a 
role in the development and progression of diseases, scientists believe it should be our 
ultimate goal to have evidence on individual genotypes to guide medicine, a development 
that would make racial identity biologically irrelevant, but that is decades away (22).
An increasing number of research studies have also suggested the possibility that 
environmental or nutritional factors could play important roles in disease progression and 
outcome. Our current study was therefore designed to assess whether environmental and 
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nutritional factors may contribute to the differences in serum ferritin concentrations 
between blacks and whites by testing the hypothesis that the presence of infection, viral 
liver diseases, alcohol consumption, nutrition and socioeconomic status are related to the 
observed difference in serum ferritin. 
 Previous studies have found that hepatitis C infected blacks were more likely to have 
increased iron stores than hepatitis C infected non-blacks (23), and their response to 
antiviral treatment was lower compared to non-blacks (24). Therefore, we were inspired 
to further explore whether there is a difference in the likelihood and magnitude on 
elevation of serum ferritin in regard to two conditions: acute inflammation and hepatitis 
C between blacks and whites. The selection of these two conditions was based on their 
significant effect on raising the serum ferritin concentrations and documented or assumed 
higher prevalence among blacks than whites. As it was discussed intensively in later 
section, the prevalence of hepatitis C has been documented to be significantly higher in 
blacks than whites. The epidemiology information for inflammation, however, is very 
limited due to lacking of the well-established model defining inflammation, especially in 
a large population. Studies have reported that African Americans have a greater 
propensity for inflammation than European Americans because African Americans are 
more likely to carry genetic variants known to stimulate the inflammatory response (26-
29). Therefore, we assume that the prevalence of acute inflammation is also higher in 
blacks than whites. 
 Although there have been different underlying mechanisms proposed for these clinical 
observations, such as different cellular immune response in the determination of the 
outcome of hepatitis viral infection and antiviral treatment response, specific variants in 
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genes that encode proteins regulating inflammation response, the further exploration and 
confirmation of these hypotheses is beyond the scope of our research. Our current study 
focused primarily on detecting the differences in the likelihood and magnitude on 
elevated serum ferritin between blacks and whites in response to two conditions. And the 
results of this investigation will not only contribute to the understanding of the ethnic 
differences in clinical outcome and treatment responsiveness, but also serve as a probe 
for future studies. 
 To our knowledge, this is the first study that attempted to assess the determinants of 
the long-observed black-white serum ferritin difference by using nationally representative 
data. The study contributed to the understanding of the ethnic differences in iron stores 
between blacks and whites, and its implications in disease disparities. We hope our 
present study can initiate more future studies to further discover the underlying 
mechanisms responsible for the observed black-white serum ferritin difference and 
clarify the relevant contribution of certain environmental factors to the exaggerated iron 




There are several categories of race/ethnicity used in the current proposal. These 
categories are sociopolitical constructs and should not be interpreted as being scientific or 
anthropological in nature.  
 
European American: a term for Americans of European descent, who are usually 
referred to as White or Caucasian. The term is more specific than White or Caucasian in 
that these terms in their official usage include European, Latin American, Southwest 
Asian, and Middle Eastern.  
 
non-Hispanic White is an official term that is more specific, but is still not as specific as 
European American. The reason for this is that 1) the term "Non-Hispanic White" 
excludes Hispanics who are of European (especially Spanish) descent, and 2) includes 
non-Europeans such as Arabs and Iranians; however, even so, when examining 
demographic data, the "Non-Hispanic White" category is that which corresponds most 
closely to European American. 
 
African Americans, also known as Afro-Americans, Black Americans, or simply blacks, 
are an ethnic group in the United States of America whose ancestors, usually in 
predominant part, were indigenous to West and sub-Saharan Africa. Many African 
Americans also have European and/or Native American ancestors.  
 
non-Hispanic Black is also an official term that is more specific, it refers to a person 
having origins in any of the black racial groups of Africa (except those of Hispanic 
origin). But it may include many African Americans also have European and/or Native 
American ancestors.  
 
Note: Unless otherwise mentioned, the term “black” and “white” used in this dissertation 





1. To determine the possible factors that may contribute to the observed difference 
in serum ferritin concentration between NHANES III non-Hispanic white and 
non-Hispanic black, male aged 20-65 years. 
2. To investigate whether there are differences in the likelihood and magnitude on 
elevated serum ferritin concentration in response to acute inflammation and 
hepatitis C, respectively, between non-Hispanic black and non-Hispanic white, 
male, NHANES III subjects, aged ≥20 years. 
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RESEARCH QUESTIONS 
1. Is there a statistically significant difference in the serum ferritin concentration 
between non-Hispanic black and non-Hispanic white, male, NHANES III subjects, 
aged 20-65 years? 
2. Is there a statistically significant difference in any of the iron-relevant dietary 
variables (total kilocalories, carbohydrate, total fat, protein, fiber, vitamin A, vitamin 
C, carotenes, iron, zinc, calcium, phosphorus and copper) between non-Hispanic 
black and non-Hispanic white, male, NHANES III subjects, aged 20-65 years? 
3. Is there a statistically significant difference in any of the iron-related serum nutrient 
indices (serum value of vitamin A, carotenes (alpha & beta carotenes, beta 
cryptoxanthin, lutein/zeaxanthin, lycopene), vitamin C, calcium, phosphorus, serum 
total protein, lead and selenium) between non-Hispanic black and non-Hispanic 
white, male, NHANES III subjects, aged 20-65 years? 
4. Is there a statistically significant difference in any of the iron status indices including 
hemoglobin (Hb), serum iron, total iron binding capacity (TIBC), serum transferrin 
satuation (TS), serum protoporphyrin (EPP), hematocrit (Hct), red blood cell count 
(RBC), red cell distribution width (RDW), mean cell volume (MCV), mean cell 
hemoglobin (MCH), and mean cell hemoglobin concentration (MCHC) between non-
Hispanic black and non-Hispanic white, male, NHANES III subjects, aged 20-65 
years? 
5. Is there a statistically significant difference in any of the infection markers including 
C-reactive protein (CRP), white blood cell count (WBC), lymphocyte number, 
mononuclear count, platelet count, plasma fibrinogen, and serum albumin between 
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non-Hispanic black and non-Hispanic white, male, NHANES III subjects, aged 20-65 
years? 
6. Is there a statistically significant difference in the following serological variables 
[aspartate aminotransferase (AST), alanine Aminotransferase (ALT), alkaline 
phosphatase (ALP), gamma Glutamyl transferase (GGT), serum total bilirubin, serum 
lactate dehydrogenase (LDH)] between non-Hispanic black and non-Hispanic white, 
male, NHANES III subjects, aged 20-65 years? 
7. Is there a statistically significant difference in the socioeconomic variables including 
mean education, poverty income ratio, or marital status between non-Hispanic black 
and non-Hispanic white, male, NHANES III subjects, aged 20-65 years? 
8. Is there a statistically significant difference in the life-style factors including alcohol 
intake, cigarette smoking, physical activity between non-Hispanic black and non-
Hispanic white, male, NHANES III subjects, aged 20-65 years? 
9. Is there a statistically significant difference in prevalence of acute inflammation, 
hepatitis C, respectively, between non-Hispanic black and non-Hispanic white, male, 
NHANES III subjects, aged ≥20 years? 
10. What proportion of the variation in serum ferritin concentration between non-
Hispanic black and non-Hispanic white, male, NHANES III subjects, aged 20-65 
years is attributed to presence of infection, liver disease, nutrient and alcohol intake, 
socioeconomic status respectively? 
11. Is there a statistically significant difference in the above mentioned proportions 
between non-Hispanic black and non-Hispanic white, male, NHANES III subjects, 
aged 20-65 years? 
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12. Is there a statistically significant difference in the serum ferritin concentration 
between non-Hispanic black and non-Hispanic white, male, NHANES III subjects, 
aged 20-65 years after removal of subjects with abnormal values of serum total 
protein, TIBC and GGT? 
13. Is there a statistically significant difference in the percentage of individuals who had 
elevated serum ferritin concentration (>300µg/L) between non-Hispanic black and 
non-Hispanic white, males, NHANES III subjects with acute inflammation and 
hepatitis C present, aged ≥ 20 years, respectively? 
14. Is there a statistically significant difference in the odds ratio of having increased 
serum ferritin concentration between acute-inflammation present non-Hispanic black 
and white, male, NHANES III subjects, aged ≥20 years? 
15. Is there a statistically significant difference in the odds ratio of having increased 
serum ferritin concentration between hepatitis C infected non-Hispanic black and 
white, male, NHANES III subjects, aged ≥20 years? 
16. Is there a statistically significant difference in the odds ratio of having elevated serum 
ferritin concentrations per unit increment of CRP, WBC, lymphocyte number, 
mononuclear count, platelet count, and serum albumin between acute-inflammation 
present non-Hispanic black and white, male, NHANES III subjects, aged ≥20 years? 
17. Is there a statistically significant difference in the odds ratio of having elevated serum 
ferritin concentrations per unit increment of ALT, AST, ALP, LDH and serum total 
bilirubin between hepatitis C infected non-Hispanic black and white, male, NHANES 




Iron and Iron metabolism
Iron, one of the most abundant metals on Earth, is essential to most life forms and to 
normal human physiology. Iron is an integral part of many proteins and enzymes that 
maintain good health. It has been found that the total body iron typically averages 4.0g 
for a man and 2.5g for a woman. The iron-containing compounds in the body can be 
grouped into 2 categories: functional (known to serve a metabolic or enzymatic function, 
for example the hemoglobin, myoglobin, cytochromes, cytochrome oxidase, and catalase) 
and storage (used for storage and transport of iron). Approximately 2/3 of total body iron 
is functional iron, most of which is in the form of hemoglobin within circulating 
erythrocytes. Other iron-containing enzymes and myoglobin make up ≈15% of functional 
iron. In men ≈1/3 of total body iron is in the form of iron stores, whereas in women only 
≈1/8 of the total is in that form. Since iron has an important role in the formation of 
hemoglobin, myoglobin and other compounds, it is necessary to understand how this 
trace element is utilized and metabolized in our body. 
 Three major factors affect iron balance and metabolism: intake, stores, and loss. The 
two determinants of iron intake are the quantity and bioavailability of iron in the diet and 
the capacity to absorb iron. Iron metabolism is unusual in that iron absorption from the 
gastrointestinal tract is the primary regulatory mechanism of iron balance (30,31). Iron 
absorption is influenced by the dietary iron content, bioavailability of dietary iron, 
amount of storage iron and rate of erythrocyte production (31). Iron availability from 
foods also varies widely. It is greatest from meat of mammalian origin, less from poultry 
or fish, and least from eggs, milk and foods of plant origin such as legumes (32,33). This 
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difference in absorbability of iron is related to the difference between heme and non-
heme iron. Non-heme iron consists mostly of iron salts, it is found mainly in plants, dairy 
products, and iron-fortified foods. Heme iron is mostly found in hemoglobin in meat, 
poultry, and fish. Although non-heme iron accounts for more than 85% of iron in the 
American diet, heme iron is 2-3 times better absorbed than the former. Absorption of 
dietary iron can occur in all parts of the small intestine, and nonheme and heme iron are 
absorbed by different mechanisms. The exact mechanism by which iron absorption is 
regulated remains uncertain, but it appears that different pathways are responsible for the 
regulation of nonheme and heme iron uptake. In case of iron deficiency, absorption is 
enhanced for both heme and nonheme iron, and enhancement of absorption is more 
pronounced for nonheme iron. 
Iron Transport
In blood or other body fluids, iron is transported by a protein called transferrin. 
Formation of transferrin depends on the combination of iron with apotransferrin. Iron 
must first be oxidized in its ferric state before it can bind to apotransferrin. 
Ceruloplasmin, a copper-containing plasma protein with ferroxidase activity, catalyzes 
the oxidation of ferrous iron to its ferric form so that it can bind tightly to apotransferrin 
in the plasma. This role of copper as part of ceruloplasmin is crucial to iron metabolism. 
Copper deficiency results in accumulation of iron in sites such as the intestine and liver, 
and reduces iron transport to tissues. 
 Transferrin transports not only newly absorbed dietary iron that has been transported 
across the basolacteral membrane of the mucosal cell but also transports iron that has 
been released following the degradation of hemoglobin. In fact, most of the iron entering 
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the plasma for distribution by transferrin is contributed from hemoglobin destruction and 
release from storage. Thus, transferrin ferries iron throughout the body delivering both 
new and recycled iron to tissues for use or for storage. Most of the iron is transported to 
the bone marrow where hemoglobin is formed, and excess iron is stored in liver 
hepatocytes and reticuloendothelial cells. 
 Cell membrane contains a protein called transferrin receptor. Transferrin receptors are 
found on almost all cell surfaces and consist of two subunits that each binds one 
transferrin molecule. Once the transferrin molecule is bound to the receptor, the 
transferrin-transferrin-receptor complex is internalized by endocytosis. Binding to 
transferrin receptors occurs in pits on the surface of the cell. Upon endocytosis, the pits 
become coated vesicles (also called an endosome), within which iron is released from 
transferrin.  
 Following endocytosis of the iron-transferrin-transferrin receptor complex in the 
coated vesicles, iron is released into the cytosol, and apotransferrin still attached to the 
membrane receptor is returned to extracellular fluid. Within the cytosol, iron is either 
transported to mitochondria where iron is inserted into protoporphyrin to form heme or is 
taken up by ferritin within siderosomes.  
Iron Storage
Iron in excess of need is stored intracellularly as ferritin and hemosiderin, principally 
in the macrophage system of liver, spleen and bone marrow. The hepatocytes of the liver 
contain about 60% of body iron; the remaining 40% is found in reticuloendothelial cells 
that are found in the spleen, liver and bone marrow.  
 Once iron is released into the cytosol, it combined with apoferritin to form ferritin, the  
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primary storage form of iron in cells. Ferritin is not a stable compound, it is constantly 
being degraded and resynthesized, thereby providing an available intracellular iron pool. 
Hemosiderin, the other iron storage protein, is thought to be a degradation product of 
ferritin, representing, for example, aggregated ferritin or a deposit of degraded apoferritin 
and coalesced iron atoms. Iron in hemosiderin can also be labilized to supply free iron, 
however the rate at which iron is released is slower than that from ferritin. 
Iron Reutilization
The avid manner in which the body converts and reutilizes iron is an important 
characteristic of iron metabolism. A normal adult catabolizes enough hemoglobin each 
day to release 20 to 25mg of iron, most of which is promptly recycled by formation of 
new hemoglobin molecules. More than 90% of hemoglobin iron is repeatedly recycled by 
phagocytosis of old erythrocytes, which occurs chiefly in macrophages of the liver and 
spleen. 
 The iron released by the action of the erythrocytic digestion is either bound to 
transferrin and ultimately redistributed for cell use or enters the storage pool as ferritin or 
hemosiderin.  
Iron Loss
Daily external losses of iron are very limited in healthy individuals [gastrointestinal 
blood (hemoglobin), 0.35mg; gastrointestinal mucosal (ferritin), 0.10mg; biliary, 0.20mg; 
urinary, 0.08mg; and skin, 0.20mg]. Additional losses of iron may occur through 
bleeding and in women this increases to 2mg a day during menstruation. 
Serum Ferritin (SF)
Ferritin and hemosiderin are the foremost iron storage compounds present primarily in  
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the liver, reticuloendothelial cells, and bone marrow (34,35). Ferritin, an iron-containing 
protein complex, found principally in the intestinal mucosa, spleen, and liver, functions 
as the primary form of iron storage in the body. In healthy persons, most iron is stored as 
ferritin ( an estimated 70% in men and 80% in women ) and smaller amounts are stored 
as hemosiderin. Ferritin is a large protein shell ( MW 450,000 ) comprised of 24 subunits, 
covering an iron core containing up to 4000 atoms of iron. Functions of ferritin range 
from short and long term storage of iron to intracellular housekeeping ( delivering iron to 
enzymes and proteins that need iron to function ) inside the cells and is very important in 
iron homeostasis.  
 Hemosiderin is aggregated ferritin partially stripped of its protein component. Unlike 
ferritin, hemosiderin is insoluble in aqueous media. Hemosiderin contains slightly more 
iron (~30% by weight) than does ferritin. In the liver and spleen of normal animals, there 
is a slight preponderance of ferritin iron over hemosiderin iron. With increasing 
concentrations of tissue iron, this ratio is reversed, and at high levels, the additional 
storage iron is deposited as hemosiderin. Both forms can be mobilized for hemoglobin 
synthesis when the need for iron exists. Reducing substances such as ascorbate, 
dithionite, and reduced flavin mononucleotide cause rapid release of iron from ferritin. 
 Ferritin is found in most cells of the body, especially macrophages, hepatocytes and 
erythrocytes. Synthesis occurs in the liver and the rate correlates directly with the cellular 
iron content. Control of ferritin synthesis occurs post-transcriptionally ( at the mRNA 
level ). There are iron- and cytokine-responsive elements in ferritin mRNA. Increased 
iron or cytokines ( such as IL-1, IL-6 ) promotes ferritin translation, resulting in increased 
iron storage. This is one of the causes of iron "sequestration" that occurs in animals in 
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terms of cutting off the supply to the invading organism with chronic or inflammatory 
disease and will reduce serum iron values. The concentration of serum ferritin correlates 
well with the amount of stored iron in normal ( and most diseased ) subjects. Serum 
ferritin concentrations are also quite stable from day-to-day, in contrast to serum iron. 
 Because of its relatively high stability and solubility, and its direct proportionality to 
body iron stores in normal individuals (36), serum ferritin is the most commonly used 
indicator of total body iron stores for normal individuals. The common cutoff for serum 
ferritin to identify low iron stores is <12µg/L for younger children and <15µg/L for adults 
(37). A serum ferritin value >200µg/L for premenopausal female and >300µg/L for male 
usually indicates increased body iron stores and warrant further evaluation for possible 
iron overload or other diseases. Table 1. depicts normal ranges of serum ferritin for adult 
males and females. 
Table 1. Normal ranges of serum ferritin for adult males and females. 
SF Concentrations 
(µg/L) 
Adult Males Adult Females 
Normal range 25–300µg/L 25-200µg/L 
Elevated >300µg/L >200µg/L (premenopausal) 
>300µg/L (postmenopausal) 
* Adapted from reference 37. 
 
The strong point of serum ferritin test is that a decrease in the amount of stored iron is 
the only known cause for a low serum ferritin result. However, an elevated serum ferritin 
concentration doesn’t necessarily indicate genuine increased stored iron. In cases of 
significant or chronic inflammatory conditions, or disease processes that cause tissue 
destruction, serum ferritin is also an acute phase reactant and can be significantly 
elevated.  
 There are several separate disease categories that can elevate serum ferritin  
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concentrations, such as iron overload, inflammation, liver disease, alcohol excess. Each 
of these categories, and their individual impact on serum ferritin concentrations, will be 
briefly discussed in the following section. 
Other Iron Status Indicators
Hemoglobin (Hb) 
 Hemoglobin is the iron-containing, oxygen-carrying pigment in red blood cells. The 
hemoglobin molecule has a molecular weight of 68,000 and is composed of 4 heme 
subunits, each with a polypeptide chain or globin attached (38). Hemoglobin plays a 
critical role in transferring oxygen from lung to tissues. Its structure of 4 hemes and 4 
globin chains provides an efficient mechanism for combining with oxygen without being 
oxidized. A remarkable feature of hemoglobin is the ability to become fully oxygenated 
during the short erythrocyte transit time in the pulmonary circulation and then to become 
largely deoxygenated as erythrocytes traverse tissue capillaries. 
 Assessment of hemoglobin status has been a commonly used parameter to assess 
nutritional status. Hemoglobin test is usually used to help diagnosing and monitoring 
anemia and polycythemia vera (a clonal disorder involving a multipotent hematopoietic 
progenitor cell in which there is accumulation of phenotypically normal red cells, 
granulocytes, and platelets in the absence of a recognizable physiologic stimulus). 
Hemoglobin is the test most commonly used to screen for iron deficiency because 
changes in Hb concentration occur at the late stages of iron deficiency. Anemia occurs 
when hemoglobin production is sufficiently depressed to result in a hemoglobin 
concentration or hematocrit (Hct) below the central 90% or 95% of range for a healthy 
reference sample of the same age and sex (39). Guidelines (Table 2.) have been 
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established for hemoglobin assessment based on sex and age of individual (40,41).
Normal range of hemoglobin is usually defined as 130-180g/L for adult male and 120-
160g/L for adult females.  
Table 2. Maximum hemoglobin concentration and hematocrit values for anemia (40,41.) 
 Hemoglobin concentration (<g/dL) Hematocrit (<%) 



























Nonpregnant and lactating women 







































* the values listed for children aged 1-<2 years can be used for infants aged 6-12 months. 
 
When an individual’s Hb concentration falls below the determined standard for his sex 
and age, he is said to be anemic. Because smoking and altitude also have impact on 
hemoglobin and hematocrit values, additional adjustments were made when hemoglobin 
concentration and hematocrit values were used in diagnosing anemia (table 3.)  
 In the United States, hemoglobin values are significantly lower among blacks than 
whites: ≈8g/L lower for adults and ≈4g/L lower for children aged <5 years. The question 
of observed difference in hemoglobin concentration may be a function of complex 
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biological, environmental and social interactions, and more sophisticated systematic 
research are required to further address the issue.  
 
Table 3 
Erythrocyte protoporphyrin (EP) 
 Another measure of iron status is Erythrocyte protoporphyrin, which is the immediate 
precursor of Hb (42). Protoporphyrin, is a metal-free porphyrin, CHN(COOH), that 
combines with iron to form the heme of hemoglobin, myoglobin, cytochrome, and other 
iron-containing proteins. EP can be easily measured using a hematofluorometer which 
requires only a couple of drops of blood and minimal technical experience (43). EP is 
elevated in the more advanced stage of iron deficient erythropoiesis as its levels increase 
slowly after the onset of iron deficiency. Raised levels of EP can also be found in 
subjects with lead poisoning and acquired defects in hemoglobin synthesis. In addition to 
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lead poisoning and iron deficiency, inflammatory conditions can also elevate erythrocyte 
protoporphyrin concentration (44,45).
This measure of iron status has several advantages and disadvantages relative to other 
laboratory measures. For example, the day-to-day variation within persons for 
erythrocyte protoporphyrin concentration is less than that for serum iron concentration 
and transferrin saturation (46). A high free erythrocyte protoporphyrin concentration is an 
earlier indicator of iron-deficient erythropoiesis than is anemia, but it is not as early an 
indicator of low iron stores as is low serum ferritin concentration (47). Inexpensive, 
clinic-based methods have been developed for measuring erythrocyte protoporphyrin 
concentration, but these methods can be less reliable than laboratory methods (44).
Transferrin Saturation (TS) 
 Transferrin saturation is the ratio of serum iron to iron-binding capacity (TIBC) and is 
the most accurate indicator of iron supply to the bone marrow. A reduction in transferrin 
saturation below 16% is a reliable index of an undersupply of iron to the developing 
erythrocyte (48). Very elevated transferrin saturation (>50% for women and >60% for 
men) is a good screening indicator for hereditary hemochromatosis (49). As with serum 
ferritin, conditions other than abnormal iron status can cause depressed or elevated 
transferrin saturation. Infections and inflammatory conditions often cause depression of 
serum iron concentrations, thereby lowering the transferrin saturation value (50).
The factors that affect serum iron concentration and TIBC, such as iron status, diurnal 
variation (46,51), and day-to-day variation within persons, can affect the measured 
transferrin saturation as well. The diurnal varation is larger for transferrin saturation than 
it is for Hb concentration or Hct (46,51). Transferrin saturation is an indicator of iron-
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deficient erythropoiesis rather than iron depletion; hence, it is less sensitive to changes in 
iron stores than is serum ferritin concentration (47,52).
Transferrin Receptors (TfR) 
 Serum transferrin receptor assay is the newest measure of iron status detecting iron 
deficiency at the cellular level. Transferrin receptors are found on cell membranes and 
allow iron-bound transferrin to enter the cell. When the iron supply is inadequate, there is 
an up-regulation of transferrin receptors to enable the cell to compete more effectively for 
iron. The number of membrane receptors is in proportion to the receptors found in 
plasma. An increase in serum receptor levels is seen in patients with iron deficient 
erythropoiesis or iron deficiency anemia. Therefore, an elevated concentration of serum 
transferrin receptors is good evidence of tissue iron deficiency. Besides iron deficiency, 
any other condition that results in a high rate of erythrocyte turnover or increased 
erythropoiesis, such as hemolytic anemia, can also cause the transferrin receptor level to 
be elevated because the iron supply can not keep up with the increased demand of heme 
synthesis (53). The cutoff value in defining an elevated transferrin receptor level based on 
normal values for adults is >8.5µg/L (54).
Unlike serum ferritin, transferrin receptor remains normal in patients with acute or 
chronic inflammation or liver disease (55) and appears to be effective in distinguishing 
iron deficiency anemia from anemia of chronic disease (56). However, because 
transferrin receptor concentration does not become depressed in iron overload, it is not 
useful in screening for or diagnosing iron overload or hereditary hemochromatosis. 
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REVIEW OF SELECTED TOPICS IN THE LITERATURE 
I.  Interpretation of an elevated serum ferritin. 
 Because the decreased amount of stored iron is the only known cause for a low serum 
ferritin value, whereas an elevation of serum ferritin is multifactorial, the interpretation of 
an elevated serum ferritin concentration becomes more important and is therefore crucial 
in the research design and result interpretation. The following section will review the 
factors come under the broad headings of: iron overload, acute inflammatory conditions, 
liver disease and alcohol excess, which can cause an elevation in serum ferritin.  
1. Iron overload 
From a general point of view, iron overload can be classified as primary or secondary 
depending on whether it results from a primary defect in the regulation of iron 
balance or is secondary to other genetic or acquired disorders. 
A. Primary iron overload.
1) Hereditary Hemochromatosis 
 In the United States most iron overload conditions are primary and the most common 
cause of primary iron overload is hereditary hemochromatosis. Hereditary 
hemochromatosis (HHC) is an autosomal recessive disorder of iron metabolism 
characterized by increased iron absorption and deposition in the liver, pancreas, heart, 
joints, and pituitary gland. Without treatment, death may occur from cirrhosis, primary 
liver cancer, diabetes, or cardiomyopathy (57).
The prevalence of hemochromatosis varies among different ethic groups, but the 
disease is most common in populations of northern European extraction. On the basis of 
screening studies using iron indices, hemochromatosis is estimated to occur in 2-5 per 
23
1000 persons in white populations in the USA. (58,59) 0.3% of Whites, 0.06% of blacks, 
and 0.03% of Mexican Americans are homozygous for the C282Y mutation ( the most 
prevalent genotype in the US ); that is, 1 in 385 individuals, approximately 718,000 
homozygous individuals are in the United States (60).  
 It was the identification of the HFE gene in the 1996 that brought a major 
breakthrough in the understanding of hereditary hemochromatosis. The HFE gene 
encodes for a novel 343-amino acid major histocompatibility complex (MHC) class I 
molecule. The exact role of HFE in iron metabolism and the means whereby mutations 
result in the increased iron absorption found in hereditary hemochromatosis are still 
unknown, but a number of potentially relevant observations have been made (61).
Missense mutations (the DNA sequence change occurs in a coding region and alters an 
amino acid) in the HFE gene, which is located on the short arm of chromosome 6 (62),
are responsible for about 85% of cases of hereditary hemochromatosis in the United 
States (63); elsewhere the proportion ranges from about 60% to 100%. The most 
prevalent ( homozygous in 83% of patients in the US ) is a C282Y mutation, a single 
mutation of G to A at nucleotide 845 results in the substitution of tyrosine for cysteine at 
amino acid 282. Amongst subjects of Northern European descent, 80-100% of those with 
clinical features of hereditary hemochromatosis are homozygous for the C282Y mutation 
(64-66). Heterozygotes are rarely to be found and are unlikely to develop the disease in 
the absence of other risk factors for iron overload but can transmit the gene mutation to 
their children. 
 Fifteen to 20 percent of the patient population is heterozygous for a different mutation 
resulting in the substitution of aspartate for histidine at amino acid 63 termed His63Asp 
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or H63D mutation. This mutation alters the biding affinity for the transferrin receptor and 
does not usually contribute to increased iron overload in the absence of the C282Y 
mutation. Patients heterozygous for both C282Y and H63D mutations are termed 
heterozygotes and only a minority of compound heterozygotes develop clinical symptoms 
of hemochromatosis (11% of cases ) (64,67,68). Patients heterozygous for either C282Y 
or H63D mutations can also develop iron overload in the setting of alcohol excess, non-
alcoholic hepatic steatosis or porphyria cutanea tarda. Whilst the C282Y mutation is 
largely confined to subjects of European extraction, the H63D mutation is much more 
widespread (69).
The third mutation resulting in a serine to cysteine substitution at amino acid 65 
(Ser65Cys or S65C ) has recently been suggested to be associated with a mild form of 
hemochromatosis (70). There are at least 38 other allelic variants of the HFE gene (71-
73). Most do not appear to be clinically significant at this time. Other forms of 
hemochromatosis, such as juvenile hemochromatosis, African iron overload disorder, are 
known to have a genetic basis but are yet to be more clearly defined (73, 74).
Given the fact that the prevalence of hemochromatosis in the United States is higher 
among European Americans than African Americans and its salient feature of 
significantly elevated serum ferritin concentration, it is reasonable for us to assume that 
the presence of hemochromatosis doesn’t contribute to the observed higher serum ferritin 
concentrations in blacks. Therefore, we decided not to include the presence of 
hemochromatosis as a factor in our primary analysis.  
2) Hereditary aceruloplasminemia 
 Hereditary aceruloplasminemia is a very rare autosomal recessive disease  
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characterized by iron overload and progressive neurodegeneration of the retina and basal  
ganglia associated with specific inherited mutations in the ceruloplasmin gene located on 
chromosome 3. The disease is caused by the absence of ceruloplasmin (Cp), a copper-
containing α2-glycoprotein found in the plasma of all vertebrate species (75). The 
epidemiology information about this disease has not been well-established so far due to 
its rareness. 
 Acting as a ferroxidase, which catalyses the oxidation of ferrous to ferric iron, a change 
required for release of iron to plasma transferrin, ceruloplasmin plays an essential role in 
the mobilization and oxidation of iron from tissue stores with subsequent incorporation of 
ferric iron into transferrin (76). A deficiency of Cu will result in iron deposition in the 
liver, pancreas, basal ganglia, and other organs. A mild-to-moderate degree of anemia 
with low serum iron and elevated serum ferritin is a constant feature of this disease (77-
80). Patients with aceruloplasminemia have hepatic iron and serum ferritin concentrations 
equivalent to those observed in persons with hemochromatosis, but are only mildly 
anemic because the nonenzymatic oxidation of iron permits some transfer of iron into 
transferrin. 
 Since aceruloplasminemia is a very rare disease in US, it won’t be included in our 
current analysis. 
B. Secondary iron overload.
This group includes iron overload either due to or associated with ineffective 
erythropoiesis, parenteral administration or ingestion of excessive amounts of iron, and 
disorders which interact with chronic liver disease and those causes of primary iron 
overload. 
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1) Iron loading anemia with or without blood transfusion. 
 Thalassemia major and sideroblastic anemia are the two best studied examples of iron 
overload secondary to blood transfusions and ineffective erythropoiesis. Because 
abnormalities in hemoglobin can decrease erythrocyte life span, the pool of erythrocyte 
precursors is markedly expanded in certain hemoglobinopathies, leading to increased 
enteral absorption of dietary iron (81-83).
Thalassemia encompasses a group of hemolytic anemias caused by inherited 
abnormalities of hemoglobin production. The disease is prevalent in the Mediterranean 
region, Middle East and Southeast Asia, and among ethnic groups originating from these 
areas. In US, approximately 1000 people are affected currently (84). There are several 
types of thalassemia that are distinguished on the basis of specific hemoglobin chain 
affected and the particular synthesis defect present. Thalassemia major (also known as 
Mediterranean anemia or Cooley’s anemia) is an inherited form of hemolytic anemia, 
characterized by hemoglobin production abnormalities. It occurs when the patient is 
homozygous for abnormal hemoglobin production, manifested as complete failure of 
beta-chain synthesis and associated with persistent production of fetal hemoglobin. 
Patients with thalassemia major present with severe anemia, hepatosplenomegaly, 
skeletal deformities, growth arrest, jaundice, and increased gastrointestinal absorption of 
iron. Transfusion is the mainstay of the care of individuals with thalassemia major. The 
purpose of transfusion is twofold; to improve the anemia and to suppress the ineffective 
erythropoiesis. Chronic transfusions prevent most of the serious growth, skeletal, and 
neurological complications of thalassemia major. However, once started, the transfusion-
related complications become a major source of morbidity, the worst of which is iron  
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overload (85).
Sideroblastic anemias (SA) are a heterogenous group of inherited and acquired 
hematopoietic disorders characterized by the association of anemia with the presence of 
non-heme non-ferritin iron deposits within the mitochondria of erythroid precursors in 
the bone marrow ( ringed sideroblasts ). It has been generally assumed that mitochondrial 
iron deposits are secondary to the failure of heme synthesis that would lead to ineffective 
erythropoiesis and increased iron absorption (82,83,86). Sideroblastic anemia is a 
complicated disorder and therefore difficult to treat. Often SA acts like iron deficiency 
anemia (IDA), but unlike IDA, iron tests are normal or increased (e.g. increased serum 
iron and ferritin) with SA and the exact cause of iron overload in sideroblastic anemia 
patients is unclear. Treatment depends on the cause; if acquired, remove the offending 
agent and anemia may disappear. In cases of severe anemia, whole red blood cell 
transfusion may be required. 
 The repeated whole blood transfusion will contribute significantly to the existing iron 
burden and worsen the iron overload situation on transfusion-dependent patients. 
Transfused blood is disposed through the macrophages of the reticuloendothelial (RE) 
system, which breaks down the hemoglobin of ingested erythrocytes (87). Thus, large 
amounts of iron accumulate as clumps of hemosiderin within the RE cells and excess 
iron, by some means, makes its way into the extracellular fluid and in the plasma until the 
capacity of apotransferrin to take up iron becomes saturated. At this point excess iron is 
delivered to the hepatocytes and other parenchymas leading to the development of organ 
damage (81,88). One unit of transfused blood (500mL) contains≈200-250mg iron from 
hemoglobin, equivalent to the amount of dietary iron absorbed over 150-200 days. 
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Transfusion of 6-12 units of blood per year can very easily lead to clinically evident iron 
overload within a few years.   
2) Porphyria cutanea tarda 
 Porphyria cutanea tarda (PCT) is a term that encompasses a group of related disorders, 
all of which arise from deficient activity of the heme synthetic enzyme uroporphyrinogen 
decarboxylase (URO-D) in the liver. PCT is a form of hepatic porphyria associated with a 
blistering skin eruption, hypertrichosis, and hepatic overproduction of uroporphyrins and 
heptacarboxyl porphyrins. It includes types that are clearly inherited (familial PCT) and 
acquired types that may occur in the context of genetic predisposition (sporadic PCT). 
The absence of a porphyria registry in the United States impedes calculation of its 
accurate frequencies (89). 
Clinical expression of both the familial type and the acquired type of PCT often 
requires exposure to inducing agents or conditions that adversely affect hepatocytes, 
particularly ethanol, estrogens, hepatitis, and human immunodeficiency viruses (HIV), 
and excess iron in the tissue associated with the presence of hemochromatosis genes or 
other causes (90). Excess iron in the tissue is frequently found in patients with PCT and 
appears to play a major role in its pathophysiology.  
3) Excessive dietary iron 
 A less common form of iron overload is related to excessive oral iron intake. The best-
known example is Bantu-type hemochromatosis, a syndrome seen among Bantu 
tribesmen in southern Africa who consume large quantities of maize beer, which is high 
in iron (40-80mg/L). The high iron content comes from the use of iron containers to brew 
the beer; the acidity of the beer increases iron solubility (91). Recent evidence suggests 
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that genetic factors may also contribute to iron overload in Africans who have very high 
iron intakes (92). But in US, this iron container induced excessive iron intake is highly 
unlikely to occur. Therefore, this reason won’t be considered as a factor in our analysis. 
 Due to the sporadic cases of these secondary iron overload diseases, we reasonably 
assume that these diseases won’t be the contributing factors to the observed serum ferritin 
difference between AAs and EAs. Therefore, they won’t be included in our analysis. 
 
Besides iron overload conditions, there is a series of non-iron overloaded situations, 
including liver disease, inflammatory conditions, and alcohol excess, which can also lead 
to increased serum ferritin concentrations. 
 
2. Liver disease 
A. Nonalcoholic steatohepatitis (NASH)
In the last few years another disease in which iron appears to have a role has become 
more important: this disease, called nonalcoholic steatohepatitis (NASH), is described as 
inflammation of the liver associated with the accumulation of fat in the liver with absence 
of alcoholism. NASH differs from the nonalcoholic fatty liver (NAFL), a simple 
accumulation of fat in the liver in that the inflammation causes damage to the liver cells 
while simple fatty liver probably does not. Also in contrast with NAFL, NASH is a 
disease that can progress to serious forms of chronic liver disease, almost 20% of patients 
with NASH progress to cirrhosis over a decade (93-96).
NASH is not connected with other causes of chronic liver disease, including hepatitis 
B and C viruses, autoimmune disorders, alcohol, drug toxicity, and the accumulation of 
copper (Wilson’s Disease) or hemochromatosis (93).
There is no known specific cause of NASH, however, The most commonly reported 
risk factors associated with NASH include obesity, type 2 diabetes mellitus, and 
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hyperlipidemia (97-100). With the increasing prevalence of obesity in the United States, 
it is currently estimated that the prevalence of NASH is 2% to 3% in the general 
population, making it the most common liver diseases in the United States. Because 
obesity and type 2 diabetes in the U.S. occur at higher rates in African Americans 
compared with white Americans, researchers hypothesized that the prevalence of NASH 
is also higher in African Americans than European Americans, but data are still limited 
on the estimates of NASH prevalence in different ethic groups. The following tables 
demonstrate current US trend of obesity and type 2 diabetes rates in different ethnic 
groups. 
 The diagnosis of NASH can be made with certainty only by examination of liver 
histology. The most frequent biochemical abnormality in the blood in NASH is persistent, 
mild to moderately elevated transaminases (ALT and AST). Increased ferritin with 
normal transferrin saturation is frequently found in patients with NASH. The elevated 
Increase in Obesity (BMI > 30) Prevalence Among U.S. Adults (Ages 20 to 74) by Racial / 
Ethnic Group and Gender 
Men Prevalence (%) Women Prevalence (%) 
Racial / Ethnic Group 1988 to 1994 1999 to 2000 1988 to 1994 1999 to 2000 
Black (non-Hispanic) 21.3  28.8  39.1  50.8 
Mexican American 24.4  29.4 36.1  40.1 
White (non-Hispanic) 20.7 27.7  23.3 30.6 
Source: CDC, National Center for Health Statistics, National Health and Nutrition Examination Survey. Health, 
United States (Table 70) 2002.  
Increase in Severe Obesity (BMI > 40) Prevalence Among U.S. Adults (Ages 20 and older) 
by Racial / Ethnic Group and Gender 
Men Prevalence (%) WomenPrevalence (%) 
Racial / Ethnic Group 1988 to 1994 1999 to 2000 1988 to 1994 1999 to 2000 
Black (non-Hispanic) 2.4  3.5  7.9  15.1 
Mexican American 1.1  2.4 4.8  5.5 
White (non-Hispanic) 1.8 3 3.4 4.9 
Source: CDC, National Center for Health Statistics, National Health and Nutrition Examination Survey. Flegal et. al. 
JAMA 2002:288:1723-7.  
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ferritin is thought to be due to the simultaneous disorder of iron and glucose and/or lipid 
metabolism, in most of the cases associated with insulin resistance. The elevated ferritin 
reflects iron overload only in those patients in whom it persists despite an appropriate 
(diabetic) diet (101).
B. Viral hepatitis
Elevation of serum iron can be found in patients with chronic hepatitis secondary to 
viral infection with hepatitis B and C, indicative of the liver inflammation but not iron 
overload.  
1) Hepatitis B 
 Hepatitis B is caused by the hepatitis B virus (HBV), a mostly double-stranded DNA 
virus in the Hepadnaviridae family. The prevalence of chronic HBV infection is high 
(>8%) in all socioeconomic groups in certain areas: all of Africa; Southeast Asia, and the 
Middle East. Data released by CDC which is based on NHANES II and NHANES III 
showed that the prevalence of HBV infection in Americans has remained at 5% over the 
past two decades. HBV infection was significantly higher in non-Hispanic blacks than 
32
whites, and prevalence of infection increased with age in all ethnic groups. The highest 
prevalence of infection was in older blacks (102). 
HBV causes acute and chronic hepatitis. The chances of becoming chronically- 
infected hepatitis patients depend upon age. About 90% of infected neonates and 50% of 
infected young children will become chronically infected. In contrast, only about 5% to 
10% of immunocompetent adults infected with HBV develop chronic hepatitis B. The 
natural history of chronic HBV infection can vary dramatically between individuals. 
Some will remain asymptomatic however are still infected, and this condition is 
commonly referred to as a chronic carrier state. Some individuals with chronic hepatitis B 
will have clinically insignificant or minimal liver disease and never develop 
complications. Others will have clinically apparent chronic hepatitis and some will go on 
to develop cirrhosis. Individuals with chronic hepatitis B, especially those with cirrhosis 
but even so-called chronic carriers, are at an increased risk of developing hepatocellular 
carcinoma (primary liver cancer) (103).
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 The risk of HBV infection remains high in the United States because of abusive 
intravenous drug use and sexual contact. HBV is transmitted horizontally by blood and 
blood products and sexual transmission. It is also transmitted vertically from mother to 
infant in the perinatal period. The risk of HBV infection is notably high in promiscuous 
homosexual men but it is also transmitted sexually from men to women and women to 
men. 
 Diagnosis of hepatitis B is based on clinical syndrome, liver function and serology test. 
Active infection is indicated by the presence of hepatitis B surface antigen (HBsAg) in 
serum (data of HBsAg are provided in NHANES III Laboratory Data File). A diagnosis 
of acute hepatitis B is recorded for those patients who also have evidence of disturbed 
liver function, symptoms and a risk history suggesting recent infection. Repeatedly 
positive HBsAg over a 6 month period in the absence of acute symptoms or risk history 
to suggest recent infection indicates a chronic carrier state. A person who has positive 
hepatitis B antibody (HBsAb) and negative HBsAg is immune and should not be further 
tested for hepatitis B. Positive HBsAb with negative core antibody is usually indicative of 
vaccination.  
2) Hepatitis C 
 Hepatitis C is a liver disease caused by hepatitis C virus (HCV), one of the most 
important causes of chronic liver disease in the United States. It accounts for about 15 
percent of acute viral hepatitis, 60 to 70 percent of chronic hepatitis, and up to 50 percent 
of cirrhosis, end-stage liver disease, and liver cancer.  
 The NHANES III survey has been used as the latest source for epidemiologic data 
about HCV. Report based on these data estimated that 1.8% (3.9 million) of the U.S. 
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population had a positive HCV antibody test, however, this rate was higher in blacks than 
among whites (3.2% versus 1.5%). The study also found that 74% of these people had 
chronic infection, and again the rate of viremia was higher in blacks than whites (86% vs. 
68%). Black men had higher rates of infection, and the highest prevalence rate was 9.8% 
among black males ages 40-49 years (102).   
Hepatitis C virus is a single stranded enveloped RNA virus that belongs to the 
Flaviviridae family. It spread primarily by contact with blood and blood products. Blood 
transfusions and the use of shared, unsterilized, or poorly sterilized needles and syringes 
have been the main causes of the spread of HCV in the United States. With the 
introduction in 1991 of routine blood screening for HCV antibody and improvements in 
the test in the mid-1992, transfusion-related hepatitis C has virtually disappeared. At 
present, injection drug use is the most common risk factor for contracting the disease 
(104).
Hepatitis C is most readily diagnosed when serum aminotransferases are elevated and 
anti-HCV (data of anti-HCV are provided in NHANES III Laboratory Data File) is 
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present in serum. The diagnosis is confirmed by the finding of HCV RNA in serum. 
Acute hepatitis C is diagnosed on the basis of symptoms such as jaundice, fatigue, and 
nausea, along with marked increases in serum ALT (usually greater than 10-fold 
elevation), and presence of anti-HCV or de novo development of anti-HCV. Chronic 
hepatitis C is diagnosed when anti-HCV is present and serum aminotransferase levels 
remain elevated for more than 6 months. Testing for HCV RNA (by PCR) confirms the 
diagnosis and documents that viremia is present; almost all patients with chronic 
infection will have the viral genome detectable in serum by PCR (105).
3) Iron and viral hepatitis 
 A link between iron and viral hepatitis was first stressed a generation ago by Blumberg 
and colleagues (106), who noted that the prognosis of acute hepatitis B was inversely 
correlated with levels of serum iron and ferritin. Specifically, patients with higher 
concentrations of serum iron or ferritin were found less likely to recover spontaneously 
from acute hepatitis B infection. Shortly after the hepatitis C virus had been cloned and 
methods for its unequivocal detection established, it was noted that many patients with 
chronic hepatitis C (CHC) had elevations in serum ferritin (107,108). These increases did 
not seem to be due solely to the fact that serum ferritin is an acute phase reactant. 
Elevations in serum iron saturations were less frequent but also noted.  
 In the great majority of patients with elevated serum ferritin and/or iron saturation in 
whom hepatic iron concentrations (HICs) were also measured, the HICs were within the 
normal range or, at most, only mildly increased (<3-fold above the upper limit of normal) 
and thus not usually thought to be hepatotoxic (109). In several careful histopathological 
studies it was shown that the lobular and cellular distribution of stainable iron in the liver 
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was correlated with therapeutic responses to interferon. Specifically, the presence of cells 
in portal tracts (stromal and endothelial lining cells) that stained positive for iron was 
associated with reduced responses to interferon. The iron staining was an independent 
and significant inverse correlate of therapeutic response, on a par with viral genotype and 
load (110).
In the 1990s higher concentrations of serum ferritin or HICs were variably associated 
with decreased likelihood of responding to standard, short-acting interferons, at the time 
the only effective antiviral therapy for CHC (109). Unfortunately, the effectiveness of 
such therapy is limited, and the costs and side effects are high. Therefore, it was a natural 
next step to suggest that iron reduction therapy might be of benefit to increase the 
response rates to interferon therapy. Indeed, this hypothesis has been confirmed in at least 
three prospective, randomized, controlled trials (111-113).
In another United States multicenter trial, patients with CHC who previously had failed 
to respond to interferon were randomized to receive iron reduction alone versus iron 
reduction plus additional interferon. Neither group achieved significant improvements in 
terms of cure of CHC, but both showed evidence of histological improvements, with less 
severe hepatic inflammation (114). These favorable effects of iron reduction alone 
confirmed and extended earlier reports showing significant improvements in serum ALT 
levels in patients with CHC who previously had not responded to interferon when they 
underwent iron reduction by therapeutic venesection (115,116).
3. Inflammatory conditions 
 Inflammation is a natural reaction to injury or infection. It is a morbid condition of any 
part of the body, consisting in congestion of the blood vessels, with obstruction of the 
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blood current, and growth of morbid tissue. It is manifested outwardly by redness and 
swelling, attended with heat and pain. While bacterial infection is often the cause of 
internal inflammation, arthritis or allergies can also be at fault. Injury is the most 
common cause of external inflammation, but allergies, infection and other factors may be 
at the root.  
 Concentrations of ferritin in the plasma are increased in acute and chronic 
inflammation as well as in certain malignancies such as Hodgkin's Disease. Because of 
its dual role as acute phase reactant, the elevated serum ferritin is more likely a reflection 
of disease activity other than iron status, especially in the case of Systemic Lupus 
Erythematosus (SLE), a chronic, usually life-long, potentially fatal autoimmune disease 
characterized by unpredictable exacerbations and remissions with protean clinical 
manifestations (117). Patients with autoimmune inflammatory diseases, such as 
rheumatoid arthritis commonly have elevated serum ferritin too. Active infection will 
also be associated with an elevated serum ferritin in the absence of iron overload. An 
elevated C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR) should alert 
one to these possibilities in patients with occult inflammation. Malignancy is another 
important cause of an acute phase reaction but is unlikely to manifest as an isolated 
elevation of serum ferritin in the absence of other clinical signs or laboratory 
abnormalities. 
 Inflammation may often be accompanied by a large number of physiologic changes, 
distant from the site of inflammation and involving many organ systems. These systemic 
changes have since been referred to as the acute-phase response, even though they 
accompany both acute and chronic inflammation. Currently, the most widely used 
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indicators of the acute phase response are C-reactive protein and erythrocyte 
sedimentation rate (118).
C-reactive protein (CRP)
C-reactive protein is a prototypical acute phase protein whose levels rise rapidly in the 
body in response to trauma, burn, or inflammatory disease. The magnitude of the 
response reflects the extent of the injury (119). CRP is often used in clinical situations as 
a non-specific screening tool for inflammatory and infectious diseases. Although the 
rising levels of CRP often complement the levels of ESR, CRP responds more quickly as 
it does not depend on fibrinogen or immunoglobulin levels, and is not affected by red 
blood cell numbers and shape. It is also not affected by anemia, polycythemia, protein 
levels, age and sex, however, all these factors are found to affect ESR, thus making CRP 
a better and more accurate marker of infection presence and tissue injury (120).
C-reactive protein is the first protein to become elevated, usually within the first 6-10 
hours of inflammation (121). It is used as a good marker of acute inflammation. CRP 
levels increase within a few hours and reach peak concentration as much as 1000-fold 
above baseline within a few days as a reaction to an infection, but they then drop back 
down rapidly after the acute infection passes (3-5 days after inflammatory stimulus). The 
half-life of CRP in serum is 6 h; thus, serum CRP concentrations decrease to normal 
within days once the infection or inflammation begins to subside (122,123). The usual 
concentration of CRP in non-infected individuals is 2mg/L or less. Mild inflammation 
and viral infections are generally associated with CRP levels of 10-40mg/L, while active 
inflammation and bacterial infection produces level of 40-200mg/L. C-reactive protein 
levels above 200mg/L are most often found in cases of severe bacterial infection and  
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burns (120).
Erythrocyte sedimentation rate (ESR)
The erythrocyte sedimentation rate (ESR), the rate at which erythrocytes settle out of 
unclotted blood in one hour, has been used as a common marker of infection presence.  
The major determinant in the sedimentation rate of erythrocytes is erythrocyte 
aggregation, which usually occurs along a single axis (rouleaux formation). The 
aggregation of erythrocytes is largely determined by electrostatic forces. Under normal 
circumstances, the erythrocytes have a negative charge and, therefore, repel each other. 
When the body is in an acute phase response to infection, many plasma proteins with 
positive charge are produced and then neutralize the surface charge of erythrocytes, 
thereby reducing repulsive forces and promoting aggregation. Therefore, infection 
presence is marked by an increase in ESR, as measured by millimeters per hour 
(124,125). An elevated C-reactive protein provides evidence of an inflammatory process 
despite a normal ESR, when used in conjunction with the ESR it greatly increases the 
sensitivity in detecting inflammatory/infectious processes, especially when variables, 
such as anemia, confound the ESR. 
Other infection parameters
Other blood parameters such as increased fibrinogen and leucocyte count and 
decreased albumin have also been identified as downstream indicators of chronic 
inflammation (126-129). However, these parameters may be affected by several 
physiopathological conditions other than an acute phase reaction (specific organ failure, 
hematologic disorders, malnutrition). Therefore, their individual specificity as 
inflammatory markers is rather poor, and none of them is likely to have, by itself, 
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sensitive indication of inflammation. Data of C-reactive protein, fibrinogen, leucocyte 
count, serum albumin and other blood parameters are provided in NHANES III 
Laboratory Data File. ESR was not performed in NHANES III, therefore, it won’t be 
used in our current analysis. 
4.    Alcohol excess 
It is well known that induction of ferritin synthesis occurs during alcohol abuse, raised 
body iron stores are found in alcoholics and heavy drinkers. Regular consumption of 
alcohol is responsible for the disruption of normal iron metabolism in humans, resulting 
in the excess deposition of iron in the liver in approximately one-third of alcoholic 
subjects (130-133).
Studies have found consistently positive relationship between alcohol intake and serum 
ferritin values in both men and women. An increase in alcohol intake was associated with 
an increase in serum ferritin concentrations. The mechanisms by which alcohol affects 
serum ferritin are unclarified, however alcohol may influence the serum ferritin in several 
ways. First, alcohol has some enhanceing effect on intestinal iron absorption, especially 
in wine drinkers, and may in this way contribute to increased body iron stores and serum 
ferritin (134). Second, alcohol may exert a toxic effect on hepatocytes and cause an 
elevation of serum ferritin through a release of intracellular ferritin (135). Third, alcohol 
may have an enhancing effect on the intracellular ferritin synthesis. 
 Not fully characterized, is the relationship between low or safe drinking levels and 
indices of body iron stores, and the factors that influence the relationship between alcohol 
and iron stores. Alcohol (>60g/day) has been shown to exacerbate liver damage due to 
iron overload. The elevation of serum ferritin caused by alcohol excess can occur without 
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elevation of other liver enzymes and often falls dramatically with abstinence from 
alcohol. 
 In the U.S., one drink is usually considered to be 12 ounces of beer, 5 ounces of wine, 
or 1½ ounces of spirits (hard liquor such as gin or whiskey) (136). Each delivers about 12 
to 14 grams of alcohol. The definition of moderate drinking is something of a balancing 
act. Moderate drinking sits at the point at which the health benefits of alcohol clearly 
outweigh the risks. The latest consensus places this point at no more than one to two 
drinks per day for men, and no more than one drink per day for women. This is the 
definition used by the U.S. Department of Agriculture and the Dietary Guidelines for 
Americans, and is widely used in the U.S. 
 The importance of conducting alcohol research among minorities is underscored by 
findings that members of many ethnic minorities in the United States report higher rates 
of heavy drinking and alcohol-related problems than do whites (137,138). Using data 
from a statewide survey of New York, Barr et al. (139) found that black men with lower 
incomes were significantly more likely than their white counterparts to report alcohol and 
other drug-related problems. Jones-Webb et al. (140) analyzed the 1984 National Alcohol 
survey and found that black men in the lower socioeconomic classes were significantly 
more likely than white men in the lower classes to report greater numbers of drinking 
consequences; but this was not true for black and white men in the higher socioeconomic 
classes. Lillie-Blanton and associates (141) reported less educated black women were 
more likely than their white counterparts to report heavier drinking, but the opposite was 
true for more educated black and white women. In 1997, Jones-Webb et al. (142) 
reanalyzed the longitudinal data from the 1984 and 1992 National Alcohol Surveys, and 
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they reported higher alcohol consumption (#drinks/month) in blacks than whites except 
black women and their white counterparts in 1984 (Table 4). 
Table 4. Mean alcohol consumption for Blacks and Whites, 1984 and 1992. 
Men Women Alcohol consumption 








1984 (year) 63.47 48.00 17.14 19.80 
1992 (year) 61.92 37.43 22.23 13.36 
* Adapted from reference 142. 
 
Based on these findings, it is reasonable to assume that alcohol consumption is higher 
among NHANES III black males than their white counterparts and this may play a role in 
the observed higher serum ferritin concentration among blacks. Therefore, the effect of 
alcohol consumption will be analyzed in our current analysis.  
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II. Investigation of iron store difference between African Americans and 
European Americans 
 
Researchers as early as 1946 have noted discrepancies between the hemoglobin 
concentrations of North American blacks and whites (143). The study was conducted by 
Milam and Muench, in which they found a fairly steady difference in hemoglobin 
concentration of 0.5-1.0g/dL between blacks and whites, with blacks consistently posting 
a lower Hb concentration. During the 1970s, decreased hemoglobin concentrations 
among blacks were shown not to be correlated with diet (144-146). In 1973, Owen et al. 
reported a difference in the Hb concentrations of 0.0-1.0g/dL between 350 white and 266 
black children of less than six years of age (144). The author proposed that the linear 
growth rate found in black children may account for the lower Hb concentration, given 
the children consumed the same amount of iron. Additionally, they also proposed that the 
possible differences in enzyme activity, specially, the enzyme 2,3-diphosphoglycerate, 
may also contribute to the Hb differences. In 1976 Garn looked again at the Hb 
differences between the two groups, this time during pregnancy (146). The study 
compared the Hb concentrations of white (n=180) and black (n=129) black pregnant 
women aged 25-40 years. The average difference in the Hb concentrations was 0.64g/dL. 
The authors concluded the difference to be significant enough to reexamine the manner in 
which Hb concentrations are used in clinical and diagnostic settings to assess presence of 
anemia and iron status, especially among the black population. Based on these observed 
differences, some researchers recommended different hemoglobin norms for blacks (147-
149).
During 1980s, a few articles attributed this reduced hemoglobin values to population 
genetic differences (150,151), while some other studies countered such claims (152-155),
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suggesting that differences resulted from hereditary hemoglobinopathies in a small 
percentage of the black population. In 1981, Williams did a thorough investigation of red 
cell indices and iron status, as well as copper and zinc status in his investigation of the 
reported differences in Hb concentration between blacks and whites (156). He measured 
white blood cell count, red blood cell count, Hb, hematocrit, MCV, MCH, MCHC, serum 
iron, TIBC, TS, serum ferritin, serum zinc, serum copper, ceruloplasmin, and glucose-6-
phosphate dehydrogenase activity in a sample size of 111 black and white, men and 
women, aged 21-60 years. Significant but inconsistent differences in Hb concentrations 
were found between two groups for each sex. Interestingly, he also found that blacks had 
a significant higher ferritin concentration compared to white, yet had a lower Hb 
concentration which may suggest a hematological abnormality, or infection presence, 
however, these were not further explored in the analysis.  
 Another study which also found a significant higher serum ferritin concentrations in 
black servicemen compared to white servicemen despite significant lower Hb values is 
the study conducted by Jackson et al. in 1983 (155). In this study, they attempted to 
control for the impact of diet and income by comparing the Hb levels of black and white 
men of similar service rank in the military. 2,599 apparently healthy servicemen were 
included in the study and blood sample was used for analyzing Hb, serum iron, serum 
ferritin, folic acid, TIBC, TS, folic acid, and serum copper and zinc. Data analyses 
showed that black males (n = 331) had a 0.27 g/dL lower mean Hb than white males (n = 
2268, P = 0.006). However, when only black (n = 60) and white (n = 371) subjects with 
known iron intakes at or above the recommended level were compared, the differences in 
the Hb of the two groups became even smaller. In the conclusion, Jackson stated that 
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although a genetic component cannot be completely ruled out at that time, nutritional 
factors appear to play an important role in Hb levels. 
 In the 1990s, some investigators again recommended that blacks might require lower 
hemoglobin/hematocrit standards (157,158), while counter claims pointed out that data 
indicating the need for dual standards were equivocal (159). In 1991, Pan and Habicht 
analyzed data from the NHANES I survey and found continued support for the call for 
separate standards, dependent on race, for assessing anemia (160). The authors concluded 
that the current standards for assessing anemia are not appropriate for the black 
population, reducing the hemoglobin cut-off by 0.5g/dL was substantial enough to justify 
a separate standard for blacks.  
 In 1992, Perry et al. attempted to explain the apparent Hb differences between blacks 
and whites by looking at the iron nutrition of subjects from NHANES II (161). Data from 
2,515 male and female subjects aged 3-12 years, or 18-45 years was analyzed for Hb 
level, Hct, serum ferritin, serum iron, transferrin saturation, TIBC, erythrocyte 
protoporphyrin and a single 24 hour dietary recall. Results demonstrated a significant 
difference in Hb levels between the two groups, after controlling for sex, age, dietary iron 
intake and serum ferritin. Similarly, it was also found that the black subjects had higher 
ferritin concentrations despite lower Hb levels. Yet, the author attributed this higher 
ferritin concentrations in the black population to a higher presence of infection, a factor 
not considered in the study. 
 Later in 1994, Johnson-Spear and Yip reported a justification for race-specific anemia 
screening criteria in a study that examined the Hb differences between 388 black and 
2,586 white women aged 18-44 years based on NHANES II data (162). Interestingly, it 
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was also Ray Yip who supported uniform standards in the assessment of anemia in a 
previous study (156).
Vacillation on this issue results partially from the failure to develop a convincing 
explanation for noted black-white differences. Despite several studies have 
simultaneously found a higher serum ferritin concentration but lower Hb concentrations 
in black populations, all the efforts were exerted to explain the differences in Hb levels, 
whereas the difference in ferritin was always ignored. In 1997, Susan Kent published a 
review article which reexamined the apparent genetic component of the observed Hb 
differences between the races (163). In the article, Kent proposed that this higher serum 
ferritin concentrations among black populations was a classic symptom of the anemia of 
infection or chronic disease. She also further suggested that blacks from all social levels 
experienced more social stress as a result of belonging to a disadvantaged group, and the 
cumulative negative impact of this stress on the individual, throughout a lifetime, will 
manifest itself in the individual’s physical and mental health. However, very few studies 
so far had examined the extent of the impact of this proposed social stress on an 
individual’s physical and mental health. 
 A recent study by Zacharski et al. examined serum ferritin concentrations by age, sex 
and race and compared the serum ferritin values with the percent transferrin saturation in 
contemporary residents of the United States (9). The sample for this study was from 
NHAHES III, consisted of 20,040 individuals >17 years of age including 8477 white, 
5484 black. 5304 Hispanic, and 775 of “other” ethnicity. Results demonstrated that serum 
ferritin concentrations rose in the late teens in men and after menopause in women. And 
this rise was more rapid and maximum ferritin concentrations were greater for blacks 
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than whites and Hispanics of comparable age and sex. Ferritin concentrations in black 
men exceeded those in whites and Hispanics for each decade of life, and differences were 
amplified with age. After menopause, ferritin concentrations in black women rose more 
rapidly and exceeded those of white and Hispanic women. Overall, they found that 
ferritin concentrations were approximately 7% to 8% greater for blacks than for whites 
and Hispanics, and differences remained throughout the second half of life. And the 
distribution of ferritin values differed from the percent transferrin saturation. The authors 
concluded that different patterns of iron accumulation exist according to age, sex, and 
ethnicity, and serum ferritin concentrations reflect graded, population-based differences 
in body iron stores. Although they didn’t further investigate why these differences exist, 
they pointed out the importance of testing iron hypothesis (disparities in iron stores 
contribute to the differences in disease among different ethnic groups) which may be 
pivotal in explaining the differences in disease prevalence between blacks and whites. 
 Despite the consistent findings of higher serum ferritin concentrations for African 
Americans than European Americans mentioned in several studies, there have not been 
any in-depth studies investigating this difference. Therefore, it is imperative, from a 
public health perspective, to better understand this consistently observed serum ferritin 
difference between black and white populations. And our current study will be the first 
one dedicated to detect the factors which contribute to the difference. 
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III. Investigations of differences in elevation of serum ferritin between African 
Americans and European Americans in regard to selected conditions. 
 
There are very few studies that examined the differences in elevation of serum 
ferritin in response to acute inflammation, and hepatitis C between AAs and EAs. And 
most of them were not directly related to this topic. The only one which appeared to be 
relevant is the study on differences in iron stores and hepatitis C.  
 In 2003, Ioannou et al. investigated differences in the relationship between hepatitis C 
infection and iron stores between blacks and nonblacks by using data from the third 
NHANES (23). The incentive of this study was to test whether differences in iron stores 
between HCV-infected blacks and nonblacks would explain the constantly described low 
response of African Americans to antiviral treatment (164-169). They determined the risk 
of having increased iron stores, defined as elevation of both serum ferritin and 
transferrin-iron saturation, in HCV-RNA-positive blacks (n=100) and nonblacks (n=126) 
relative to HCV-RNA-negative blacks (n=4,002) and nonblacks (n=10,943). They also 
compared the magnitude of elevation in serum markers of iron stores in patients with 
abnormal liver enzymes and patients with normal liver enzymes. Subjects aged ≥17 years 
were included in the analyses, those who had advanced cirrhosis, with missing data on 
tested variables were excluded from the analysis. The results found that HCV-positive 
blacks were 5.4 times more likely to have increased iron stores than HCV-positive 
nonblacks. Blacks showed a larger difference in the proportion of persons with increased 
iron stores between HCV-positive and HCV-negative persons compared to other 
ethnicities. HCV-positive blacks with abnormal liver enzymes also had an increased risk 
of having increased iron stores. The authors concluded that blacks had a greater 
proportion than persons of other ethnicities respond to HCV infection with an increase in 
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iron stores. This striking difference in iron markers between blacks and nonblacks was 
unlikely related to differences in the presence of acute inflammation, since they adjusted 
for C-reactive protein in their analysis and CRP levels didn’t affect those observations. 
Therefore the findings may partly explain why black HVC-infected patients are more 
resistant to antiviral treatment relative to whites since studies found that iron depletion by 
phlebotomy in patients with HCV had improved response to interferon. Although the 
study was limited by lack of using hepatic iron concentration, which is a better predictor 
of response to interferon and a more accurate marker of iron store, previous studies have 
shown that serum ferritin and TS had a good correlation to hepatic iron concentration 
(170-172). Particularly that liver biopsy is not yet a standard test performed in large 
population-based studies. This finding, in turn, is an evidence of iron hypothesis that 
differences in iron stores may contribute to the differences in diseases among ethic 
groups, which may also have important clinical implications.      
 Unlike the study of hepatic C infection and iron stores, there have been no published 
reports investigating the disparities in iron stores with regard to acute inflammation 
among ethic groups. It appears that most attention was focused on the relationship 
between ethnicity and cytokine genes (25-29). Most studies reported that African 
Americans have a greater predisposition to inflammation because of the more up-regulate 
inflammation cytokine genotypes found in them.      
 Ness et al. (25) recently compared genetic data on 179 African-American and 396 
white women who sought prenatal care and delivered uncomplicated, single, first births at 
Magee-Womens Hospital of the University of Pittsburgh Medical Center between 1997 
and 2001. Blood samples were analyzed for a multitude of functionally relevant allelic 
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variants in cytokine-regulating genes. Among these were several genes regulating the 
immune system proteins interleukin-1, interleukin-1 alpha, interleukin-1 beta, 
interleukin-6, interleukin-10, interleukin-18 and tumor necrosis factor-alpha (TNFA). 
They found that the proinflammatory cytokine interleukin-6 IL6-174 G/G genotype was 
36.5 times (95% confidence interval (CI): 8.8, 151.9) more common among African 
Americans. Genotypes known to down-regulate the antiinflammatory interleukin-10 
(IL10-819 T/T and IL10-1082 A/A) were elevated 3.5-fold (95% CI: 1.8, 6.6) and 2.8-
fold (95% CI: 1.6, 4.9) in African Americans. Cytokine genotypes found to be more 
common in African-American women were consistently those that up-regulate 
inflammation. The results were consistent with the previous study conducted by Hoffman 
et al. (26), in which they also found that African Americans to be more likely to have 
cytokine polymorphisms with functional consequences of a predisposition to higher level 
of proinflammatory cytokines and lower levels of immunosuppressant. Other studies (27-
29) also showed ethnic variation in allelic distribution in cytokine genes, including TNFA 
, ILIA, ILIB, IL2, IL6, IL12, and IFNG (interferon-γ) and increased CD80 and CD86 




I. Survey Description and Sample Design 
 The National Health and Nutrition Examination Surveys (NHANES) are a series of 
national surveys that the National Center for Health Statistics, Center for Disease Control 
and Prevention (CDC), began conducting in 1966 to estimate the prevalence and risk 
factors for common diseases in the U.S. population. The third NHANES was the seventh 
in this series, conducted from 1988 to 1994, utilizing 89 survey locations that were 
randomly divided into two sets or phases, the first consisting of 44 locations, the second 
consisting of 45 locations. The NHANES survey used complex, stratified, multi-stage, 
clustered samples of civilian, non-institutionalized populations. A detailed description of 
design specifications and copies of the data collection forms can be obtained in the Plan 
and Operation of the Third National Health and Nutrition Examination Survey, 1988-
1994 (173,174). In total, 39,695 persons were selected over the six-year period; of those, 
33,994 (86%) were interviewed in their homes. All interviewed persons were invited to 
the Medical Examination Center (MEC) for a medical examination. 30,818 (78%) of the 
selected persons were examined in the MEC; an additional 493 persons ere given a 
special limited examination in their homes. 
Data Preparation and Use of Sample Weights 
The NHANES III data CD-ROM (175), obtained from the National Center for Health 
Statistics, served as the source of data for this study. The NHANES III data files consist 
of five separate data sets; the Household Adult Data File, the Household Youth Data File, 
the Examination Data File, the Laboratory Data File, and the Dietary Recall Data File. 
Data from the Household Adult Data File, the Examination Data File and the Laboratory 
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Data File were included in this analysis (176-178). Detailed specimen collection and 
processing instructions were discussed in the Manual for Medical Technicians (174). The 
multi-level data collection and quality control system were discussed in detail in the Plan 
and Operation of the Third National Health and Nutrition Examination Survey, 1988-
1994 (173,174). All interview, laboratory, and examination data were sent to NCHS for 
final processing. Details on survey instruments and forms, training manuals, and data 
collection procedures were documented elsewhere (179).
The variables included in this study were selected based on the impact that they exert 
either directly or indirectly on serum ferritin concentrations of participants. The impacts 
have already been discussed in detail in the literature review section. Because the data 
sets for the third NHANES were in a SAS format, therefore, SAS was used to sort the 
data sets, obtain the desired variables, and merge the data from the three data sets into 
one final data set. The sequence or identification number allowed for extracting the 
variables of interest from each of the data files (Household Adult Data File, the 
Examination Data File, the Laboratory Data File) and merging the extracted data to form 
the final data set.  
 Because of the complex survey design of the third NHANES, appropriate sample 
weights were applied in all analyses to adjust for the complex survey design effect. By 
weighting the sample data, analysts are able to produce estimates of statistics that would 
have been obtained if the entire sampling frame (for NHANES III, the entire sampling 
frame is the United States) had been surveyed. Sample weights can be considered as 
measures of the number of persons the particular sample observation represents. 
Weighting takes into account several aspects of the survey: the specific probabilities of 
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selection for the individual domains that were over-sampled, as well as non-response, and 
differences between the sample and the total US population. Differences between the 
sample and the total population may arise due to the sampling variability, differential 
under coverage in the survey among demographic groups, and possibly other types of 
response errors, such as differential response rates or misclassification errors. Since 
NHANES III over-sampled non-Hispanic blacks and Mexican-Americans, children under 
5, and the elderly people (≥60y), the population weights were used in all analyses to 
account for over-sampling, multi-stage sampling design, and nonresponse to the 
household interview and the examination. The sample weight used in this study was 
selected based on the recommendation from the National Center for Health Statistics, and 
is the appropriate sample weight when data from both phases of the survey are being 
analyzed as a whole.  
II. Statistical Software 
 The newly released SAS version 9.1 was used to prepare the data source for our 
analysis including sorting, extracting, merging and assumption testing of the data set. The 
new version of SAS 9.1 incorporated some survey procedures to analyze complex survey 
data. SUDAAN 9.0 also has the capability to use all of the design variables from multiple 
stage sampling and does not need to assume sampling with replacement. In survey 
analysis packages, the variance estimation using SUDAAN’s linearized Taylor series 
with unmasked all stage sampling information is considered to be the most accurate 
method among all softwares that take complex sampling structure into account. 
Therefore, our final data set was analyzed by using the SUDAAN and SAS statistical 
software packages. 
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III. Primary Analysis 
1.   Study Sample 
 A total number of 3,554 non-Hispanic white (NHW) and non-Hispanic black (NHW) 
male subjects, aged 20-65 years, with available serum ferritin concentration was included 
in this study. Among them, 1,938 were NHWs and 1,616 were NHBs. Due to the impact 
each has on ferritin, the subjects who were hemophiliacs and subjects who had recently 
undergone chemotherapy were excluded from the analysis. Subjects who had been treated 
for anemia (include diet, iron pills, iron shots, transfusions as treatment) within past 3 
months and who had blood donation within one month before the survey were also 
excluded from the analysis. We only chose males to eliminate the additional, potential 
confounding effects such as growth, menstruation, birth control pills, pregnancy, parity, 
menopause or hormone replacement therapy associated with females. Adult males aged 
20-65 years were selected because studies have shown that serum ferritin concentrations 
remain stable during adulthood but tend to rise after the age of 65 years, due to either 
increased iron stores or the effect of progressive development of inflammatory diseases 
(180,181).
2.  Variables  
 Since our goal is to identify the possible factors which contribute to serum ferritin 
difference between NHWs and NHBs, variables that either directly or indirectly affect 
serum ferritin concentration were included in our analysis based on the existing 
knowledge of ferritin metabolism. Because the potential variables encompass different 
postulations of their impacts on serum ferritin, we divided them into different categories 
for sub-regression analyses in order to further reduce the number of variables to be placed 
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in the final regression model. Variables were grouped together and placed into one of the 
following six sub-categories: dietary variables (including alcohol intake), serum nutrient 
indices, hematological markers, infection markers, serological markers, and 
socioeconomic variables. 
 Dietary variables are the ones that we first considered as the variables influence iron 
nutrition and iron stores. Dietary intakes including carbohydrate, total fat, protein, fiber, 
vitamin C, vitamin A, carotenes, iron, zinc, calcium, phosphorus and copper were 
examined from the 24-h dietary recall data.  
 Carbohydrate, total fat and protein are the major constituents of a person’s diet and are 
the basic indices used to assess one’s nutritional status. Inadequate energy or nutrient 
intake will compromise the status of health and nutrition. The consequence of 
compromised nutrition and health status could then lead to impaired erythropoiesis and 
decreased iron stores. Fiber and zinc are the inhibitors of iron absorption. Fiber-
associated decreased diffusion rate of nutrients result in diminished absorption of most 
nutrients including iron. Zinc inhibits iron absorption by competing for the same portion 
of a common absorptive pathway (183). Calcium and phosphorus are thought to interact 
with iron and inhibits its absorption through Fe:Ca:PO4 chelate formation at the intestinal 
mucosa. Several studies have demonstrated that ingestion of calcium in amounts of 300 
to 600 mg when given up to 18 mg iron as ferrous sulfate or when incorporated into food 
substantially decrease iron absorption by up to 70% (184-188). The term vitamin A is 
used to refer to retinol, and many but not all carotenes can be converted into retinol. Iron 
status is also interrelated with vitamin A. Reduced vitamin A status alters iron 
distribution between tissues. Studies in experimental animals showed that low plasma 
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retinol concentrations are associated with decreased plasma iron and blood hemoglobin 
and hematocrit as well as increased hepatic iron accumulation. It appears that the 
mechanism of interaction between vitamin A and iron is an impairment in the 
mobilization of iron from the liver and/or incorporation of iron into the erythrocyte. 
Vitamin A also may be directly acting on iron metabolism or storage or may be affecting 
differentiation of the red blood cell (189,190). The interaction between iron and vitamin 
C is related not only to the vitamin’s effect on intestinal absorption of nonheme iron but 
also on the distribution of iron in the body. Specifically, ascorbate enhances the intestinal 
absorption of nonheme iron by either reducing iron to a ferrous form from a ferric form 
or by forming a soluble complex with the iron in the alkaline pH of the small intestine to 
thereby enhance iron’s absorption. The effect of the vitamin C in the distribution and 
mobilization of storage iron has also been demonstrated, however, the underlying 
mechanisms are still uncertain (191,192). Copper is also believed essential for the 
production of red blood cells and plays a role in the transport and utilization of iron. 
Without the copper-dependent ferroxidase activity, iron cannot be mobilized from ferritin 
stores.  
 Alcohol intake was indicated as the total number of alcoholic drinks consumed by 
participants per month. In the Household Adult Questionnaire, participants were asked to 
report their consumption of beer (“lite” beer included), wine (wine coolers, sangria, and 
champagne included), and hard liquor (gin, rum, whiskey, tequila, vodka, liqueurs, etc) in 
times/mo. One drink of alcohol was described as 12 oz (360mL) beer, 4 oz (120mL) 
wine, or 1 oz (30mL) hard liquor. The total number of alcoholic drinks consumed by 
participants was therefore computed by adding the numbers of drinks of beer, wine, and 
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hard liquor. Alcohol consumption was then further divided into 4 categories: nondrinker 
(0 drinks/mo), light drinkers (1-30 drinks/mo), moderate drinkers (31-60 drinks/mo), 
heavy drinkers (>60 drinks/mo). 
 In addition to dietary intake, the manner in which a person utilizes these nutrients for 
various metabolic processes also has impact on iron status. Therefore, serum nutrient 
indices include the actual serum value of retinol, carotenes (alpha & beta carotenes, beta 
cryptoxanthin, lutein/zeaxanthin, lycopene), vitamin C, calcium, phosphorus, serum total 
protein, lead and selenium were analyzed. Here we included lead because it interacts with 
iron. Lead inhibits the activity of ∆-aminolevulinic acid dehydratase, an enzyme required 
in heme synthesis. Lead also inhibits ferrochelatase activity, the enzyme that 
incorportates iron into heme. In addition, increased absorption of lead occurs with iron 
deficiency in animals, but the mechanism through which iron deficiency improves lead 
absorption is unknown (193). Iron is also thought to interact with selenium, but the 
mechanism behind is not known. Iron deficiency is associated with decreased selenium 
concentrations as well as glutathione peroxidase synthesis and activity (194,195). Since 
NHANES didn’t have data for zinc and copper serum values, we were not able to assess 
the serum levels for these nutrients. The dietary intake for selenium and lead was not 
provided in NHANES III. 
 As direct assessment of iron status, the hematological markers including hemoglobin 
(Hb), serum iron, total iron binding capacity (TIBC), serum transferrin satuation (TS), 
serum protoporphyrin (EPP), hematocrit (Hct), red blood cell count (RBC), red cell 
distribution width (RDW), mean cell volume (MCV), mean cell hemoglobin (MCH), and 
mean cell hemoglobin concentration (MCHC) were included in our analysis. Each 
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parameter of iron status contributes to the understanding of ferritin concentrations by 
reflecting changes in different body iron compartments and different levels of iron 
depletion. Although a low serum ferritin concentration defines the onset of iron 
deficiency, it does not indicate the severity of the iron deficiency due to higher assay 
variability. Therefore, additional measurements such as TS or transferrin receptor (not 
available in NHANES III) will need to be taken in order to further differentiate the stages 
of iron deficiency. Correct interpretation of elevated serum ferritin concentrations relies 
on both using the appropriate gender and age specific reference range and conjunction 
with other iron status indicators since serum ferritin concentrations may also increase in 
the presence of acute inflammation, infection, anemia of chronic disease (normal to 
elevated), malignancy, liver disease and alcohol excess other than genuine increased iron 
stores. Data on these variables are provided in NHANES III Laboratory Data File. 
 Another major focus of this analysis is to investigate whether the presence of infection 
contributed to the observed serum ferritin difference between NHBs and NHWs. 
Therefore, a set of infection markers; variables that are indicative of presence of 
infection are included: C-reactive protein (CRP), white blood cell count (WBC), 
lymphocyte number, mononulear count, platelet count, plasma fibrinogen, serum 
albumin. Data on these variables are provided in NHANES III Laboratory Data File. 
 Because serum ferritin also increases with presence of liver diseases, e.g. hepatitis C, 
the following serological variables which are indicative of the presence of liver disease 
were included: aspartate aminotransferase (AST), alanine aminotransferase (ALT), 
alkaline phosphatase (ALP), gamma glutamyl transferase (GGT), serum total bilirubin, 
serum lactate dehydrogenase (LDH), and hepatitis C antibody (anti-HCV), which was 
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used to identify the presence of hepatitis C. Data of these variables are also provided in 
NHANES III Laboratory Data File. 
 As a part of environmental effect, socioeconomic variables including education, 
poverty income ratio (PIR), and marital status are considered to have indirect impact on 
an individual’s health and iron status. Education was measured as the highest year or 
grade completed by the respondent, and was further dichotomized as higher than high 
school or less than high school education. Poverty income ratio (PIR) is based on total 
household income adjusted for household size and the cost of living at the time of the 
study. It is used as an eligibility criterion for participation in federal and state economic 
assistance programs and as an index of relative socioeconomic status in NHANES III 
survey. We used 3 PIR strata: <1.3, 1.3-3.5, and >3.5 to represent low income level, 
moderate income level and high income level, respectively according to the analytic and 
reporting guidelines of NHANES III (196). Marital status was divided into two categories 
as married including living as married, and unmarried including being widowed, 
divorced, separated or never married. 
 Other variables that may have affected serum ferritin were adjusted for in the statistical 
analyses to reduce residual variance in the outcomes and to control for potential 
confounding. These variables included age, ethnicity, body mass index (BMI; in kg/m2), 
cigarette smoking and physical activity. BMI was further divided into 4 categories: 
underweight (BMI<18.5), normal (18.5≤BMI<25), overweight (25≤BMI<30), obese 
(BMI≥30). Cigarette smoking was classified as never smoked (if they had smoked <100 
cigarettes in their lifetime), former smoker (≥100 lifetime cigarettes, not currently 
smoking), and current smoker (≥100 lifetime cigarettes, currently smoking). Physical 
60
activity, which is a composite measure of the frequency of exercise in the last month and 
the intensity rating (metabolic equivalent) of each activity, was calculated by summing 
the activities in the last month and was divided into 3 categories: sedentary (<20th 
percentile), moderate (<60th percentile), and active (≥60th percentile). 
 In addition, disease prevalence including anemia, arthritis, acute inflammation, cancer 
(various types), congestive heart failure, diabetes mellitus, heart attack, hypertension, 
emphysema and stroke were also compared between NHWs and NHBs. Status of 
arthritis, cancer, congestive heart failure, diabetes mellitus, heart attack, emphysema and 
stroke was determined by the response to the question of whether a doctor has ever told 
the respondent that he/she had such diseases. Undiagnosed diabetes was identified by 
having a fasting plasma glucose concentration >126mg/dL (197) or currently talking 
insulin. Hypertension was defined as having systolic blood pressure ≥140mmHg or/and 
diastolic blood pressure ≥90mmHg (198), or if a doctor has told the participant that he or 
she had hypertension. Anemia was defined as having a hemoglobin concentration 
<13g/dL in men according to the World Health Organization (WHO) criteria (199). 
Acute inflammation was detected by having a serum CRP concentration ≥1.0mg/dL 
(123,200). Presence of elevated serum ferritin was defined as having serum ferritin 
>300µg/L in men (37). 
3. Statistical Analysis 
 Descriptive statistics were computed for all variables, including means for continuous 
data, frequencies for categorical variables, and standard error of the mean (SEM). 
Geometric mean was used to present the mean serum ferritin and protoporphyrin 
concentration because of their right skewed data distribution. SUDAAN’s t-test and Chi-
61
square test were applied to compare the means of all continuous variables and 
frequencies of all categorical variables between NHBs and NHWs, respectively. 
Statistical significance was set at a p value<0.01 for both t-test and χ2 test. 
 Multiple regression analysis was used to examine the possible variables which 
contribute to the variation in SF concentrations. Due to the large number of regressors 
under each category, separate sub-regression models were carried out with SF 
concentration as the dependent and ethnicity as a covariate for each set of variables 
including dietary variables, serum nutrient indices, hematological markers, infection 
markers, serological markers, and socioeconomic variables. Variables that achieved 
p<0.05 from each sub-regression model were considered significant and were retained in 
the final regression models. Two final regression models with serum ferritin as dependent 
variable were carried out with or without adjustment of additional confounders. Statistical 
significance was set at a p value <0.01 for the final regression models. Least square 
means (LS means) of SF were also computed based on each regression model to compare 
the SF difference between NHWs and NHBs, after controlling for different factors. 
 Multicollinearity among independent variables for each regression model was tested by 
checking the variance inflation factor (VIF). Any variable with a VIF that exceeded 4 
was excluded from the model. Therefore, phosphorus intake was excluded from the 
regression analysis (VIF=6.72). Because of highly correlated data among dietary intakes 
of carbohydrate, protein and fat, the percent calorie from these nutrients were placed in 
the regression model instead. In the sub-model containing hematological markers, 
hematocrit was excluded because of its high correlation with hemoglobin value. Only 
MCV was retained in the model because of its high correlation with MCH and MCHC. 
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Log-transformation was used to correct the highly skewed data distribution of 
protoporphyrin. Because SF was positively skewed, the regression analyses were 
repeated using log-transformed ferritin values as the dependent, and the results were 
compared between the models with different dependent variables.  
 Before running the multiple regression models, those variables with ≥10% missing 
data were eliminated from the analysis. Therefore, plasma fibrinogen was removed from 
the sub-regression model containing infection markers because of its unacceptable 
percent of missing value (50%). Unless otherwise mentioned, the appropriate sample 
weights (WTPFHX6), stratum variable (SDPSTRA6) and primary sampling unit (PSU) 
variable (SDPPSU6) were applied to all analyses to account for the complex design effect 
and nonresponse. 
IV. Supplemental Analyses 
1.  Study Sample 
 In our study, we are also interested in investigating whether the likelihood and 
magnitude of serum ferritin elevation in response to two conditions (acute inflammation, 
and hepatitis C) are different between NHBs and NHWs. Therefore different study 
populations were used for each condition.  
 A serum CRP concentration ≥ 1.0mg/dL is widely accepted as indicative of an active 
acute phase response (200). Therefore, for acute inflammation, 235 NHW and 164 NHB 
males, aged ≥ 20 years with CRP ≥ 1.0mg/dL were included in the final analysis. 
 Study population for hepatitis C included non-Hispanic black and non-Hispanic white 
males, aged ≥ 20 years with presence of positive serum hepatitis C antibody. Because 
hepatitis C could proceed to liver cirrhosis, and advanced cirrhosis secondary to any 
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cause is associated with iron overload (201-203), we wanted to evaluate the risk of 
having increased serum ferritin in the absence of advanced cirrhosis for hepatitis C. In 
NHANES III, no questions were asked regarding the presence of cirrhosis, and liver 
biopsy was not included in the survey, which is the gold standard for diagnosing 
cirrhosis. Therefore, we attempted to identify participants at risk of having advanced 
cirrhosis based on the methods used in the previous studies (204,205): presence of either 
a serum albumin less than 3.5g/dl, a platelet count less than 100,000/µL, or a total serum 
bilirubin greater than 2.0mg/dL. Subjects who fulfilled at least 1 criterion as well as 
identified as hepatitis C were excluded from the analysis. Subjects with sickle cell 
diseases were also excluded from analysis. Therefore, the final study population for 
hepatitis C consists of 62 NHW and 92 NHB male subjects. 
2. Variables 
a. Acute inflammation 
 Presence of elevated serum ferritin was defined as having serum ferritin concentration 
>300µg/L in men (37). Disease prevalence including cancer (various types), congestive 
heart failure, diabetes mellitus, heart attack, hypertension, and stroke were also compared 
between NHWs and NHBs. Status of cancer, congestive heart failure, diabetes mellitus, 
heart attack, and stroke was determined by the response to the question of whether a 
doctor has ever told the respondent that he/she had such conditions. Undiagnosed 
diabetes was identified by having a fasting plasma glucose concentration >126mg/dL 
(197) or currently taking insulin. Hypertension was defined as having systolic blood 
pressure ≥140mmHg or/and diastolic blood pressure ≥90mmHg (198), or if a doctor has 
told the participant that he or she had hypertension.  
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 Several inflammation markers including plasma fibrinogen, serum albumin, white 
blood cell count (WBC), lymphocyte number, monocyte number and platelet count were 
examined. Other laboratory variables including serum iron, transferrin saturation (TS), 
total iron binding capacity (TIBC), total triglycerides (TG), total cholesterol, HDL and 
LDL cholesterol were also compared between NHWs and NHBs. Additional confounders 
including BMI, education, and cigarette smoking were also included in the statistical 
model. The description of these variables has been discussed in the previous section for 
primary analysis. 
b. Hepatitis C 
 The percent of hepatitis C (HCV) infected individuals who had elevated serum ferritin 
concentrations were compared between NHW and NHB. Disease prevalence including 
cancer (various types), congestive heart failure, diabetes mellitus, heart attack, 
hypertension, and stroke were compared between current NHW and NHB subjects 
(description of variables was mentioned in above section). Several serological markers 
including aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline 
phosphatase (ALP), gamma glutamyl transferase (GGT), serum total bilirubin, serum 
lactate dehydrogenase (LDH) were examined and were compared between NHWs and 
NHBs. Other laboratory variables including Hb, serum iron, TS, TIBC, CRP, WBC, 
platelet count, serum albumin were also included in the analysis. Additional factors 
including BMI, education and cigarette smoking were also controlled for the potential 
confounding effects in the statistical model. 
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3. Statistical Analysis 
a. Acute inflammation 
 The aim of our analyses was, first to investigate whether there is any differences in the 
likelihood of having elevated serum ferritin concentrations in response to acute 
inflammation between NHWs and NHBs. This was examined by using logistic regression 
models to compare the odds ratios of having elevated serum ferritin values between 
NHWs and NHBs controlling for the potential confounding effects.  
 The second goal of our analyses was to investigate whether the magnitude of having 
elevated serum ferritin concentrations in response to acute inflammation was also 
different between NHWs and NHBs. We examined this by using logistic regression 
analysis to compare the odds ratios per unit increment in several inflammation markers 
including CRP, WBC, serum albumin, lymphocyte count, monocyte count and platelet 
count adjusting for the potential confounders. 
 Logistic regression models were carried out with adjustment of several potential 
confounders including age, PIR, ethnicity, education, BMI, cigarette smoking, status of 
cancer/congestive heart failure/heart attack/diabetes mellitus/hypertension/stroke, and 
cardiovascular disease risk factors such as triglycerides, total cholesterol, HDL 
cholesterol, LDL cholesterol, and waist circumference because of their known 
relationship to CRP (206-209). Variables including LDL cholesterol and waist 
circumference were excluded from logistic regression analyses because of their 
unacceptable percent of missing value (LDL cholesterol: 59.65%, waist circumference: 
15.54%). Multicollinearity among independents for each logistic model was tested by 
checking the variance inflation factor (VIF).  
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 In our analysis, SUDAAN’s t-test was used to compare the means of all continuous 
variables between NHWs and NHBs. SUDAAN’s Chi-square test was used to compare 
the frequencies of all categorical variables between these two groups. Logistic regression 
analysis was applied for our likelihood and magnitude tests. The statistical significance 
level was set at a p<0.05 for all analyses. Unless otherwise mentioned, sampling weights 
were applied to all analyses to account for the complex design effect and nonresponse.  
b. Hepatitis C 
 Logistic regression models were applied to compare the odds ratio of having increased 
serum ferritin concentration (>300µg/L) between NHW and NHB HCV-infected male 
subjects (likelihood test). Logistic regression was also used to estimate the odds ratios of 
having elevated serum ferritin concentration per unit increment in several serological 
markers including AST, ALT, ALP, LDH and serum total bilirubin between NHWs and 
NHBs with adjustment of age, ethnicity, PIR, BMI, CRP and alcohol consumption 
(magnitude test). GGT was excluded from the analysis because of high percent of 
missing value (35.6%). 
 Descriptive statistics were computed for all variables, including means, standard error 
of the mean (SEM) for continuous data and frequencies for categorical variables. Logistic 
regression analysis was applied for our likelihood and magnitude tests. The statistical 




I. Primary Analysis 
Descriptive statistics 
Serum ferritin (SF) difference 
 Crude differences in mean serum ferritin concentration were evident in all age groups 
and were greater in NHBs than NHWs at each age (Fig. 1). Overall, the mean SF 
concentration of NHBs was significantly higher than that of NHWs (SF 
difference=37.06µg/L, p<0.0001). Compared to NHBs, NHWs had significantly higher 
percent of subjects with normal (25-300µg/L) SF concentration (84.49% vs. 78.95%, 
p=0.0005) but lower percent of having elevated (>300µg/L) SF concentration (12.72% 
vs. 19.64%, p<0.0001) (Table 3). 
Subject characteristics 
 The final data set included 3,554 males aged 20-65 years. Among them, there were 
1,938 NHW males and 1,616 NHB males. The average age of NHWs was significantly 
older compared to NHBs. NHBs had a significantly lower PIR with greater percent of 
people having low income but lower percent of people having high income compared to 
NHWs. A significantly greater percent of NHWs remained married or living as married 
whereas a significantly higher percent of NHBs were unmarried. Overall, NHWs 
achieved a significantly higher level of education compared to NHBs. The prevalence of 
chronic diseases was similar between the two groups, as was the presence of arthritis, 
cancer (various types), congestive heart failure, diabetes mellitus, heart attack, 
emphysema and stroke. However, the percent of NHBs who had anemia, acute 
inflammation, hepatitis C and hypertension was significantly higher than NHWs. There 
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was no statistically significant difference between NHWs and NHBs for BMI, physical 
activity, and alcohol consumption. However, the number of NHWs who had moderate 
level of exercise was significantly higher compared to NHBs. In addition, there was a 
greater percent of NHBs who were current smoker, but the percent of former smoker was 
significantly higher among NHWs (Table 1). 
Nutrient intakes and serum status 
 The data indicated that overall, the energy and nutrient intakes were higher among 
NHWs than NHBs, with the exceptions of protein and vitamin C. Intakes of 
carbohydrate, fiber, iron, zinc, copper, calcium and phosphorus were significantly higher 
in NHWs. Compared to NHWs, a significant higher percent of NHBs only had iron 
intake <10mg/d, and fewer of them had iron intakes ≥10mg/d. The percent calorie from 
carbohydrate was significantly higher in NHWs whereas the percent calorie from protein 
was significantly lower in them. Among the serum nutrient indices, NHW subjects had a 
statistically higher serum retinol, serum vitamin C, serum lycopene, and serum selenium 
concentration, while NHB subjects had statistically higher values for serum total protein, 
serum β-cryptoxanthin, serum lutein/zeaxanthin, serum phosphorus and blood lead 
(Table 2). 
Biochemical markers 
 For the hematological markers, NHWs were found to have significantly higher values 
for serum iron, Hb, HCT, MCV, MCH, MCHC, TIBC and TS compared to NHBs. RDW 
levels were significantly higher among NHBs. Compared to NHWs, there was a 
significantly higher percentage of NHB subjects who were anemic (Hb<13g/dL), while 
the percent of NHB with normal Hb value was significantly lower. 
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 Several infection markers including CRP, lymphocyte count, plasma fibrinogen, were 
found significantly higher among NHBs than NHWs. The values for WBC and serum 
albumin were significantly lower in NHBs compared to NHWs. Among the serological 
markers, NHWs had statistically lower AST, ALP, GGT and LDH concentrations, while 
NHBs had statistically lower values for serum total bilirubin (Table 3). 
Inferential statistics 
 Because there is no significant difference in the results obtained from regression 
models using serum ferritin concentrations as the dependent variable and regression 
models with log-transformed serum ferritin concentrations as the dependent variable, 
results of the regression analysis using serum ferritin concentration as the dependent 
variable were used as the final results for interpretation purposes. Table 4 showed the 
results for different sub-regression models. For each sub-model, the NHB ethnicity was 
consistently found to be associated with higher SF concentrations compared to the NHW 
ethnicity after controlling for other variables. Different sub-regression models resulted in 
a SF difference between NHWs and NHBs ranging from 24.66µg/L to 47.6µg/L.  
 For the first sub-regression model containing nutrient and alcohol intakes, percent 
calorie intake from carbohydrate and fat as well as calcium intake were found to be 
inversely associated with SF concentration. For the sub-model containing serum nutrient 
indices, serum concentrations of total protein, retinol, α-carotene, β-cryptoxanthin, 
lycopene, and phosphorus were significantly associated with SF. In the sub-model for 
hematological markers, MCV, TIBC and log-transformed protoporphyrin were 
significantly associated with SF concentration after controlling for other iron status 
indicators. CRP was the only infection marker found to be positively associated with SF 
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concentration in the sub-model of infection markers. After adjustment for hepatitis C 
status, GGT was the only serological marker found to be significantly associated with SF 
concentration. Compared to the subjects who were widowed, divorced, separated or never 
married, being married or living as married was positively associated with SF 
concentration. Having an education level higher than high school was associated with a 
lower SF concentration compared to having an education level lower than high school. 
 In the two final regression models, ethnicity was no longer found to be significant after 
controlling for the factors within each model. The first final model running with all the 
significant variables obtained from each sub-regression model showed that being 
married, serum total protein, serum retinol, MCV and GGT were positively associated 
with SF concentration while %kcal from carbohydrate, calcium intake, serum α-carotene, 
and TIBC were inversely associated with SF concentration. After further controlling for 
age, BMI categories, cigarette smoking and physical activity in the second final 
regression model, the above-mentioned association remained significant except for being 
married and serum retinol, but the additional significant effect of age, %kcal from fat and 
BMI on SF concentration was found. Results of these were shown in Table 5.
Proof test 
 Since the results of regression analyses only identified the significant variables 
associated with the serum ferritin concentration, additional analysis was needed to further 
investigate how these variables may explain the difference in SF concentrations between 
NHBs and NHWs. Therefore, a proof test was carried out by using a revised regression 
model built on the second final regression model to further prove the contribution of 
serum total protein, TIBC and GGT to the observed SF difference. The model was run 
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after excluding the subjects with abnormal values of serum total protein, TIBC and GGT. 
The normal ranges for these measurements were defined as: serum total protein: 6-
8.5g/dL (32); TIBC: 240-450µg/dL (33); GGT: <50U/L (34).           
 When such subjects were included in the analyses (final regression model 1 and 2), the 
final regression models resulted in a reduction of 25.61µg/L and 25.73µg/L from initial 
SF difference (37.06µg/L) between NHWs and NHBs, respectively. Elimination of the 
subjects with abnormal values of serum total protein, TIBC and GGT from the analysis 
resulted in a remarkable reduction of 33.11µg/L from initial SF difference, and the SF 
difference between NHWs and NHBs dropped to 3.95µg/L (p=0.5886) (Table 6).  In the 
revised regression model, BMI, %kcal from carbohydrate and fat, calcium intake, and 
MCV were no longer found to be significantly contributing variables, however, age, 
serum total protein, serum α-carotene, TIBC and GGT continued to have a significant 
association with SF concentration (Table 5). 
II. Supplemental Analysis 
a. Acute inflammation 
Descriptive statistics 
 The proportion of subjects who had elevated serum ferritin concentrations (>300µg/L) 
in regard to acute inflammation stratified by age and ethnicity were shown in Fig. 2.
NHB generally showed a higher proportion of individuals with elevated serum ferritin 
concentrations with regard to acute inflammation than their white counterparts for each 
age group. The greatest ethnic differences in the percent of individuals with elevated SF 
concentrations were seen at age of 40 to 49 years.  
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 The comparisons of subject characteristics between NHB and NHW were shown in 
Table 7. Among individuals with presence of acute inflammation, the percent NHBs who 
had elevation in SF concentrations was significantly higher than that of NHWs (35.23% 
vs. 21.78%, p=0.0080). Generally, NHBs were younger, poorer, less likely to be former 
smoker but more likely to smoke currently compared to NHWs. NHWs had a 
significantly higher percent of individuals who had higher than high school education 
compared to NHBs. NHBs had a significantly higher percent of individuals who had low 
income but a significantly lower percent of individuals with high income compared to 
NHWs.  
 Overall, there was no significant difference in disease prevalence including cancer, 
congestive heart failure, diabetes mellitus, heart attack, hypertension and stroke between 
these two groups. Values of CRP, serum albumin, platelet count, plasma fibrinogen and 
lymphocyte were comparable between NHWs and NHBs. However, NHWs were found 
to have significantly higher values of WBC and mononuclear count compared to NHBs. 
Compared to NHWs, NHBs had significant lower values of Hb (p=0.0006), but their 
serum ferritin concentrations were significantly higher (p=0.0052). Significant 
differences in HDL and LDL cholesterol were also found between these two groups 
(p=0.0054 and 0.0139, respectively). 
Likelihood Test 
 As shown in Table 8, NHB males with presence of acute inflammation were 2.153 
times more likely (95% CI, 1.234 to 3.754) than their white counterparts to have 
elevations in serum ferritin (>300µg/L) after adjustment for age, ethnicity, PIR, 
education, BMI, smoking status, and disease status. When the relationship was further 
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adjusted for cardiovascular disease risks including triglycerides, total cholesterol, HDL 
cholesterol, systolic and diastolic blood pressure, NHBs were associated with a 2.239-
fold greater risk (95% CI, 1.333 to 3.760) of having elevated serum ferritin in regard to 
acute inflammation than NHWs. 
Magnitude Test 
 The odds ratios of having elevated serum ferritin concentrations associated with each 
increment in selected inflammation markers were calculated for NHBs with NHW as the 
control group (Table 9). Every increment of WBC, serum albumin, lymphocyte count 
and platelet count was associated with significantly higher odds ratios of having elevated 
SF concentrations among NHBs than NHWs in both reduced and full logistic models. 
Without further adjustment of cardiovascular disease risks, per unit change in CRP was 
not associated with significantly higher risk of having elevations in SF among NHBs than 
NHWs. When the relationship was further controlled for cardiovascular disease risks in 
the full logistic regression model, every unit change in CRP was associated with 
significantly higher odds ratios of having elevation in SF among NHBs than NHWs. 
However, no significant differences in the odds ratios of having elevated SF 
concentrations with unit change in monocyte count were found between NHBs and 
NHWs. 
b. Hepatitis C 
Descriptive statistics 
 Subject characteristics of HCV (hepatitis C virus) infected male participants aged ≥20
years old were shown in Table 10. Compared to NHWs, NHBs were older, poorer, 
leaner, with less percent of individuals who achieved higher than high school education, 
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and consumed more alcohol. Prevalence of congestive heart failure and hypertension was 
higher among NHBs, whereas prevalence of heart attack and stroke was higher among 
NHWs. Compared to NHWs, NHBs had a higher prevalence of having elevation in serum 
ferritin concentration (39.91% vs. 20.90%). The percent of HCV infected individuals 
who had abnormal liver enzyme values (AST or ALT >40U/L) was also higher among 
NHBs than NHWs (59.82% vs. 35.67%). Compared to their white counterparts, 
hemoglobin values were found lower among NHBs, however their SF concentrations are 
higher. Overall, NHBs had higher values of liver enzymes including AST, ALT, ALP, 
GGT, LDH and serum total bilirubin compared to NHWs. 
Hepatitis C genotype distribution 
 Distribution of hepatitis C genotypes between NHB and NHW HCV infected males 
was shown in Fig. 3. The number of subjects carrying each HCV genotype was shown in 
Table 11. Genotype 1 was the most common genotype in both NHWs and NHBs 
(60.15% and 57.58%, respectively). The second most predominant genotype among 
NHWs and NHBs were genotype 4 (18.87%) and genotype 2 (30.60%), respectively. 
HCV genotype 3 was the least frequent genotype found in both NHWs and NHBs (1.18% 
and 3.65%, respectively). 
Inferential statistics 
 The results of likelihood test didn’t find significant differences in the odds ratios of 
having elevated serum ferritin concentrations between NHBs and NHWs in regard to 
HCV infection (Table 12). Unit change in selected serological markers including AST, 
ALT, LDH and serum total bilirubin were not associated with significantly different odds 
ratios of having elevation in SF between NHB and NHW HCV infected subjects. (Table 
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13). Without further adjustment for cardiovascular disease risks, per unit change in ALP 
was not found to be associated with significantly higher risk of having elevations in SF 
among NHBs than NHWs. When the relationship was further controlled for 
cardiovascular disease risks in the full logistic regression model, every unit change in 
ALP was associated with significantly higher odds ratios of having elevation in SF 





I.  Primary Analysis 
 
Although the higher serum ferritin concentrations have been continuously reported 
among blacks despite their lower hemoglobin values compared to whites, the etiology of 
this noted SF difference remains unknown. This study therefore served as the first 
attempt to explore this long-observed black-white SF difference. As a direct support to 
one of the overarching goals of Healthy People 2010 to eliminate health disparities 
among populations, our results sought to answer the question of why there is a difference 
in iron stores between blacks and whites, and what are the factors contributing to this 
difference that underlie the “iron hypothesis” (213, 214). In accordance with the results 
from other studies (6-9), our data indicated a continuing, significantly higher serum 
ferritin concentration among NHB males aged 20-65 years compared to their NHW 
counterparts. Overall, NHB subjects were shown to have a significantly higher SF 
concentration than NHW subjects. Controlling for one category of factors at a time by 
using different sub-regression models resulted in a SF difference ranging from 24.66 to 
47.6µg/L between these two groups. However, after adjustment of all the significant 
variables obtained from each sub-regression model, the two final regression models 
resulted in a significant reduction in SF difference (25.61µg/L & 25.73µg/L, 
respectively), therefore suggesting that the putative mechanism that may underlie the 
marked black-white SF difference is complex.  
 The current results indicated that iron nutrition did not account for the SF difference 
between NHBs and NHWs.  Instead, variables including %kcal from carbohydrate, %kcal 
from fat and calcium intake were found to be significantly associated with SF 
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concentration in the final regression models. The inverse relationship between calcium 
intake and ferritin concentration may be related to the fact that simultaneous ingestion of 
calcium inhibits iron absorption by competing for the same portion of a common 
absorptive pathway (186-188), and thus decreasing the amount of absorbed iron to be 
incorporated into the apoferritin. The observed inverse relationship between percent 
energy from macronutrients and SF may reflect the impact of the overall nutrition and 
diet on ferritin metabolism, however, more specific investigations are needed to further 
elucidate the mechanism underlying. 
 The significant associations observed between serum total protein, serum α-carotene 
and SF suggest a relationship between health status and SF concentration. As a two-faced 
protein, ferritin also serves as an acute phase reactant which concentrations in the plasma 
can be increased in both acute and chronic inflammation, and the elevated SF is more 
likely a reflection of disease activity other than iron stores. Since serum total protein is a 
commonly tested measurement used to evaluate overall health status, liver and kidney 
function as well as nutritional status, our current finding could be the reflection of the 
strong interaction between overall health status and ferritin metabolism. The significant 
inverse association observed between serum α-carotene and SF may be linked to the role 
of α-carotene played in the antioxidant defense system against oxidative stress induced 
by inflammatory stimuli (215). However, future studies are needed to clarify the 
biological mechanisms. 
 In our study, the association between iron status and ferritin metabolism was indicated 
by the significant associations between MCV, TIBC and serum ferritin. The effect of 
TIBC on SF in particular, suggested the strong relationship between body iron status and 
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ferritin homeostasis. TIBC measures the amount of added iron that can be specifically 
bound by plasma transferrin. Greater than normal level of TIBC is usually symbolic of 
iron deficiency, and reduced level is associated with acute inflammation, chronic 
infections, renal disease and malignancy (39). Therefore, the inverse relationship between 
TIBC and ferritin may reflect the alterations of ferritin metabolism in iron deficiency and 
diseases. 
 The observed significant association between GGT and SF may reflect the crucial 
linkage between hepatic well-being and ferritin economy. GGT is an enzyme which is 
found in hepatocytes and biliary epithelial cells. Its serum measurement provides a very 
sensitive indicator of the presence or absence of hepatobiliary disease, and is often used 
as an indicator for a variety of chronic diseases and alcoholism (212). The strong 
relationship observed between GGT and SF highlights the critical role the liver plays in 
the ferritin homeostasis. In addition, age was found positively associated with SF 
concentrations, and it is likely due to the higher probability of having chronic 
inflammatory diseases associated with older age. The current results also indicated that 
marital status and BMI could influence the SF concentration, however, the effect is more 
likely due to the nutritional and health status influenced by socioeconomic factors.      
 An essential part of our analysis was to uncover some of the factors that may account 
for the long-observed SF difference between NHWs and NHBs. This was achieved by 
carrying out a revised regression model (proof test) based on the hypothesis that further 
adjustment of the selected contributors would result in similar SF concentrations between 
NHWs and NHBs, or further reduce the difference in SF concentration. Serum total 
protein, TIBC and GGT were chosen as the contributors to be further controlled in the 
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proof test, given their roles of reflecting the strong associations between overall health 
and nutrition, iron status, hepatic well-being and serum ferritin. As expected, removal of 
the subjects with abnormal values of these indicators resulted in comparable SF 
concentrations between NHBs and NHWs, and the SF difference was no longer 
significant (SF difference=3.95µg/L, p=0.5586). Therefore, the results suggest that the 
differences in overall nutrition and health, iron status and hepatic well-being may be 
responsible for the observed difference in SF between NHBs and NHWs. 
 Serving as the major synthetic site of ferritin protein, liver plays a pivotal role in 
ferritin homeostasis. Hepatic ferritin synthesis is strongly influenced by 
pathophysiological conditions including inflammation and malignancy, and the 
inflammatory cytokines such as interleukin 1 (IL-1), interleukin-6 (IL-6) and tumor 
necrosis factor-α (TNFα) can alter the hepatic ferritin gene transcription (217). Hepatic 
inflammation or injury is usually accompanied by elevations in serum ferritin, and is 
thought to be a result of an up-regulated ferritin production as an acute phase reactant in 
response to inflammatory stimuli (90). Our data indicated that the overall liver function 
was better among NHWs compared to NHBs since several serological markers including 
AST, ALP, GGT and LDH were found significantly higher among NHBs. Plus the fact 
that hepatitis C was more prevalent among the current NHB study population and the 
previous findings of the higher likelihood of carrying genetic variants encoding 
inflammatory cytokines including IL-1, IL-6 and TNFα among blacks (25-27), the 
observed higher ferritin concentration in blacks may be a result of the higher frequencies 
of liver disease and the more aggressive cytokine-induced ferritin synthesis responsive to 
inflammation. But more studies are required to further assess the association. 
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 Although the current results didn’t find a significant contribution of infection to the SF 
difference, the role of inflammation in the etiology of black-white SF difference merits 
further investigation. Note that several infection markers were found significantly 
different between NHWs and NHBs in our analysis, thus suggesting higher frequencies 
of infection among blacks than whites. Interestingly, several characteristics 
corresponding to the definition of the anemia of chronic disease (ACD) were also found 
in our current NHB subjects, thereby suggesting the possible contribution of ACD to the 
observed SF difference. ACD is generally a normochromic or slightly microcytic anemia 
resulting from chronic infection, chronic immune activation, or malignancy, and is 
clinically characterized by reduced serum iron concentrations, TS and TIBC, with normal 
or elevated SF concentrations (218). ACD is distinguishable from iron deficiency anemia 
(IDA) because SF is reduced whereas TIBC should be high in genuine IDA. In our study, 
NHBs were found to have lower Hb, serum iron, MCV, TS and TIBC but higher SF 
concentrations compared to NHW subjects, thus suggesting a higher frequency of this 
condition among blacks. Unfortunately, neither bone marrow examination nor transferrin 
receptor, which can provide more definitive diagnosis of ACD was available in 
NHANES, therefore, we couldn’t quantify the contribution of ACD to the observed SF 
difference. Moreover, our efforts of further assessing the existence and contribution of 
chronic inflammation to the observed SF difference between NHBs and NHWs were 
hampered by the limited availability of infection markers. In contrast to CRP, which is 
the short-term indicator of infection, erythrocyte sedimentation rate (ESR), fibrinogen 
and α1-acid glycoprotein (α1-AGP) are thought to best reflect the resolution, or the long-
term status of the inflammation (219). However, none of them were included in our study 
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due to either unavailablility in NHANES III (ESR & α1-AGP) or high percent of missing 
data (plasma fibrinogen). Hepcidin, a recently discovered hepatic antimicrobial protein 
(220-222), provide new hope to the research of ACD, however has not yet become a 
routinely performed test. Given the interaction of hepcidin with the iron exporter 
ferroportin, and its role in the regulation of iron transport and recycling, future 
investigation using hepcidin may shed light on the role of ACD in the etiology of the 
black-white SF difference in the future.  
 In addition to the limited availability of biomarkers, other limitations of our study 
should also be acknowledged. First, owing to the cross-sectional design, causal inferences 
of the identified factors and SF concentration cannot be drawn. Secondly, due to the 
potential confounding effects associated with female subjects, only male subjects were 
included in our study, therefore, the results cannot be inferred to the female population. 
Thirdly, because the data for cytokine measurements were not available in NHANES III, 
we were unable to determine the role of cytokine-induced ferritin synthesis in the black-
white SF difference. Furthermore, because genetic information was not available in 
NHANES III, our current study cannot rule out the possibility that genetic polymorphism 
may play a role in the etiology of SF difference. Though hypothesis generating in nature, 
future studies should address these questions. 
 In summary, this study highlighted the necessity and importance of future studies that 
can bring more insights to this long-observed black-white serum ferritin differences. Our 
results suggest that the noted black-white SF difference is a result of factors including 
overall nutrition and health, iron status and hepatic well-being. Higher SF, low Hb and 
reduced TIBC level observed in blacks are consistent with the definition of ACD. More 
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specific investigations using cytokines, hepcidin or other infection markers are needed to 
further determine the role of ACD in the etiology of the SF difference between blacks 
and whites. 
II. Supplemental Analysis 
a. Acute inflammation 
 In the present study, we observed a significantly higher percent of NHBs with present 
acute inflammation had elevated SF concentrations than their NHW counterparts. And 
the percent of NHBs who had raised SF was consistently higher than that of NHWs at 
each age group. Compared to NHWs, NHBs were more likely to have elevated SF 
concentrations in regard to acute inflammation after adjustment for potential 
confounders. Therefore, the results raised a possibility that there might be different 
modes of responsive ferritin synthesis during inflammatory process between blacks and 
whites. 
 Cytokines directly regulate ferritin secretion both transcriptionally and 
posttranscriptionally. A number of cytokines including interleukin 1 alpha (IL-1α), 
interleukin 6 (IL-6), tumor necrosis factior alpha (TNFα) have been shown to up-regulate 
ferritin production (223-226). Proinflammatory cytokines TNFα and IL-1α
transcriptionally induce the H chain of ferritin. As a result, the selective induction of 
ferritin H mRNA will lead to the accumulation of a population of H-rich ferritin protein 
and substantially increase the content of ferritin (223-225). In primary cultured human 
hepatocytes, IL-1α and IL-6 can induce a transient secretion of ferritin at 24 hours 
followed by a decline to baseline (226). Results from these studies suggest another 
possibility that the differential patterns of raised ferritin observed between blacks and 
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whites could be a result of different cytokine-induced ferritin synthesis during 
inflammation. However, prospective studies are required to test the hypothesis. 
 In our study, NHBs demonstrated a greater capability and propensity to have increased 
store iron than NHWs in regard to acute inflammation. The observed disparate pattern of 
ferritin increase may be a result of the different cytokine genotype distribution between 
blacks and whites. Several studies have shown that significantly different allelic and 
genotypic cytokine distribution exists between blacks and whites (25-28). Most studies 
reported that blacks have a greater predisposition to inflammation because of the more 
up-regulated inflammation cytokine genotypes found in them, IL-1α, IL-6 and TNFα in 
particular. Therefore, the higher risks of having raised SF observed among inflammation- 
infected blacks may be the functional consequences of their predisposition to the higher 
level of proinflammatory cytokines which are known to stimulate ferritin secretion. 
 The current results also showed that every increment of selected inflammation markers 
was associated with higher risks of having elevated SF in NHBs than in NHWs. The 
stronger inflammation-ferritin relationship observed in blacks raise the possibility that the 
presence of amplified increase in stored iron may predispose blacks to worse clinical 
outcomes and poorer treatment response. Since ferritin plays a prominent role in the 
cytokine response and inflammatory processes, the more aggressive iron accumulation 
pattern reflected by raised serum ferritin in inflammation may reflect the greater intensity 
of inflammation and the stronger host immunoresponsiveness underlie a number of 
physiological and pathological processes. But further investigation is needed to confirm 
the association. 
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 To date, little is known about the underlying mechanisms of the disease disparities 
highlighted by the strikingly higher morbidity and mortality rates among blacks. 
Compared with whites, blacks have approximately 1.5 times higher death rates from all 
causes, worse survival after myocardial infarction (10), a 2-fold-higher incidence of and 
morbidity from stroke (11,12), and significantly higher morbidity and mortality rates 
from diabetes (14), AIDS (15), and cancer (16). Given the fact that ferritin plays a pivotal 
role in the cellular inflammatory response and pathogenesis of disease, the question of 
whether there is a difference in the responsive ferritin synthesis during inflammation 
between blacks and whites, and whether the differences in stored iron play a role in 
disease disparities merits further research. 
 Observations over the last few decades have also identified ethnic differences in 
response to therapies in many diseases, including hypertension (227-229), diabetes (230), 
renal transplantation (231-232), heart failure (233), and depression (2342). In addition, 
there are striking ethnic differences in response to interferon therapy for hepatitis C 
(HCV). Long-term sustained responses to alpha interferon are substantially lower among 
black patients than white patients with hepatitis C (24,235-238). Interestingly, the fact 
that iron depletion by phlebotomy in patients with HCV reduces serum aminotransferase 
levels (239-244), and in combination with interferon, may have improved antiviral 
efficacy compared with interferon alone (240,242,244) suggests that increased store iron 
may be the cause of the reduced response to interferon. Although the presence of 
increased store iron is a recognized predictor of poor response to interferon monotherapy 
(245-252), the association between increased store iron and treatment response for other 
diseases has not yet been investigated adequately. Therefore, larger, prospective studies 
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are required to evaluate whether the different patterns of increase in stored iron are 
associated with different therapy response among various ethnicities. 
 To our knowledge, this is the first study to assess the association between acute 
inflammation and iron stores between blacks and whites. Despite that the fact that ethnic 
differences in disease burden, progressions, complications, outcomes and treatment 
response have been observed between blacks and whites, the explanation for this remains 
unclear. Of great interest is to find out whether there is ethnic difference in the 
inflammatory process and host immnoresponsiveness that underlie a variety of clinical 
pathophysiological conditions. Given the pivotal role ferritin plays in the cellular 
inflammatory response, our study was conducted to test the hypothesis that there is ethic 
difference in the relationship between acute inflammation and iron stores reflected by 
serum ferritin concentration between blacks and whites. Within this work, we presented 
evidence that blacks had a more aggressive rise in serum ferritin with regard to acute 
inflammation compared to whites. And the stronger inflammation-ferritin relationship 
observed in blacks may reflect their more robust immune response and therefore may 
contribute to the poorer prognosis. But more prospective data are required to further 
investigate the hypothesis. 
 Despite the significant findings of our study, our analysis is not powered to address the 
underlying mechanisms of the observed ethnic differences in iron stores during acute 
inflammation. Therefore, more specific investigation is needed to further explore the 
responsible biological rational. However, our study does raise the possibility that the 
different patterns of iron accumulation may play a role in disease processes and result in 
different clinical outcomes and drug response. Future studies will address this topic.  
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 In conclusion, the current results indicated that different patterns of iron accumulation 
in regard to acute inflammation exist between NHWs and NHBs. Further elucidation is 
needed about how ferritin regulation is perturbed in diseases, and whether increased 
stored iron plays a role in different clinical outcomes and drug response. To which extent 
that different stored iron contribute to the ethnic disparate response to disease and 
treatments requires further investigation. A more complete knowledge on the etiology of 
the differences in host inflammatory response could provide clinicians with the ability to 
optimize the therapeutic regimens tailored to the individual. 
b. Hepatitis C 
 Our current data showed that hepatitis C is approximately twofold more prevalent 
among NHBs (6.02%) than among NHWs (2.94%). The results of HCV genotype 
distribution indicated that genotype 1 was the most common HCV genotype among both 
groups. This result is in accordance with the previous report based on NHANES III data, 
in which it also documented a higher prevalence of genotype 1 among NHBs with 
predominance of genotype 1b (253). 
 Previous studies have shown that raised serum ferritin was an independent predictor of 
non-response to antiviral treatment in patients with chronic hepatitis C infection, and 
HCV-infected blacks are less likely to respond to anti-HCV therapy (234-238). Of great 
interest is to assess whether the differences in the stored iron is responsible for the 
differences in antiviral treatment response among various ethnicities, especially between 
blacks and whites. Therefore, our analysis was carried out to investigate the relationship 
between HCV infection and patterns of raised serum ferritin between NHWs and NHBs.  
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 In general, the results of our analysis showed no difference in the likelihood and 
magnitude of having elevated SF concentrations in regard to HCV infection between 
NHW and NHB males. By contrast, a recent study also using data from NHANES III 
suggested that NHB individuals may respond to HCV infection with an increase in iron 
stores reflected by both elevated serum ferritin and transferrin saturation, which may be 
partly responsible for the reduced efficacy of antiviral therapy (23). In this study, Ioannou 
et al. found that HCV-infected blacks were 5.4 times (95% CI, 1.2 to 24) more likely to 
have increased iron stores than nonblacks. The increased risk of elevated iron stores 
among HCV-positive black persons persisted despite adjusting for age, alcohol intake, 
gender, socioeconomic status, and BMI (odds ratio 17.8; 95% confidence interval, 5.1 to 
63).  
 The conflicting results may be due, in part, to two reasons. First, our efforts to assess 
the association between hepatitis C and increased iron stores between NHWs and NHBs 
may have been hampered by the paucity of HCV infected subjects included in our 
analysis. Despite the significant findings that Ioannou et al. found from their study, the 
extremely high upper CI values are suggestive of inadequate statistical power and small 
sample size. Therefore, the stability and reliability of their statistical analyses are 
questionable. Secondly, both studies were limited by the fact that hepatic iron index, 
which is a better indicator of body iron stores and predictor of IFN response, was not 
available in NHANES III. Therefore, future study by using hepatic iron concentration is 
required to further determine the relationship between iron stores and the course of HCV, 
as well as the response to therapy. 
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 Although the HCV genotype information was available in NHANES III, the data was 
not sufficient enough for us to further investigate the relationship between the ethnic 
differences in genotype predominance and the increase in iron stores. However, emerging 
data have shown that genotype is the most critical predictor of anti-HCV treatment 
response. Studies have clearly indicated that patients with genotypes 1a or 1b have poorer 
responses to treatment with either IFN monotherapy, or standard or pegylated IFN plus 
ribavirin combination therapy than patients with genotypes 2 or 3 (254-256). Therefore, 
the linkage between HCV genotypes and the responsive change in iron stores among 
different ethnicities merits further investigation. 
 Despite the fact that we didn’t find significant results in our current analysis, the role 
of iron accumulation in hepatitis C is worthy of further investigation. Adequately 
powered and sized prospective trials are needed to further investigate the hypothesis that 
differences in the stored iron may be responsible for the differences in anti-HCV therapy 





Subject characteristics in NHANES III non-Hispanic white and non-Hispanic black males, aged 20-65 yrs.1





n mean SEM n mean SEM  
Age (y) 1938 39.73 0.38 1616 37.49 0.37 <0.0001*
Education (yr) 
 ≤12 yr (%) 






















Poverty income ratio (PIR) 
 <1.3 (%) 
 1.3-3.5 (%) 
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Prevalence (%)        
 anemia  71 3.04 0.79 154 8.53 0.82 <0.0001*
elevated SF concentration 274 12.72 0.87 324 19.64 1.25 <0.0001*
acute inflammation 82 3.50 0.51 117 6.37 0.60 0.0007*
congestive heart failure 40 1.23 0.22 36 1.94 0.36 0.1026 
 diabetes mellitus 125 5.12 0.56 125 6.82 0.60 0.0343 
 heart attack 86 2.90 0.40 41 2.31 0.40 0.3289 
 hepatitis C 46 2.94 0.55 86 6.02 0.93 0.0041*
hypertension  358 15.16 1.16 375 20.69 1.03 0.0016*
emphysema 0 0  0 0   
 stroke  22 0.96 0.23 22 0.98 0.25 0.9573 
BMI (kg/m2)
<18.5 (%) 
 18.5-25 (%) 
 25-30 (%) 





































 sedentary (%) 
 moderate (%) 






























 non-drinker (%) 
 light drinker (%) 
 moderate drinker (%) 




































Smoking status  
 non smoker (%) 
 former smoker (%) 





























1. The means of all continuous variables were compared between non-Hispanic white and non-Hispanic black male 
subjects using SUDAAN’s t-test. The frequencies of all categorical variables were compared between non-Hispanic 
white and non-Hispanic black male subjects using SUDAAN’s Chi-square test.  
* Statistical significance is set at a p<0.01. 




Dietary intake and serum nutrient status among NHANES III non-Hispanic white and non-Hispanic black 






n mean SEM n mean SEM  
Dietary intakes 
 total energy intake (kcal) 
 carbohydrate (g) 
 protein (g) 
 total fat (g) 
 %kcal from carbohydrate (%) 
 %kcal from protein (%) 
 %kcal from fat (%) 
 fiber (g) 
 dietary iron (mg) 
 <10 (%) 
 ≥10 (%) 
 vitamin A (RE) 
 carotenes (RE) 
 vitamin C (mg) 
 zinc (mg) 
 copper (mg) 
 calcium (mg) 






































































































































Serum nutrient status 
 total protein (g/dL) 
 serum retinol (µg/dL) 
 vitamin C (mg/dL) 
 α-carotene (µg/dL) 
 β-carotene (µg/dL) 
 β-cryptoxanthin (µg/dL) 
 lutein/zeaxanthin (µg/dL) 
 lycopene (µg/dL) 
 total calcium (mg/dL) 
 phosphorus (mg/dL) 
 selenium (ng/mL) 




























































































1. The means of all continuous variables were compared between non-Hispanic white and non-Hispanic black male 
subjects using SUDAAN’s t-test. The frequencies were compared between non-Hispanic white and non-Hispanic black 
male subjects using SUDAAN’s Chi-square test.  




Biochemical markers among NHANES III non-Hispanic white and non-Hispanic black males, aged 20-65 yrs.1





n mean SEM n mean SEM  
Hematological markers 
 serum iron (µg/dL) 
 serum ferritin (µg/L)2
<25 (%) 
 25-300 (%) 
 >300 (%) 
 hemoglobin (g/dL) 
 <13 (%) 
 13-18 (%)  
 hematocrit (%) 
 RBC (106 cells/mm3)
RDW (%) 
 MCV (SI, fL) 
 MCH (SI, pg) 
 MCHC (SI) 
 TIBC (µg/dL) 
 TS (%) 





































































































































plasma fibrinogen (mg/dL) 


























































 AST SI(U/L) 
 ALT SI (U/L) 
 ALP SI(U/L) 
 GGT SI(U/L) 
 serum total bilirubin (mg/dL) 


















































1. The means of all continuous variables were compared between non-Hispanic white and non-Hispanic black male 
subjects using SUDAAN’s t-test. The frequencies were compared between non-Hispanic white and non-Hispanic black 
male subjects using SUDAAN’s Chi-square test.  
2. Arithmetic means of serum ferritin were compared between non-Hispanic white and non-Hispanic black male subjects 
using SUDAAN’s t-test. 









NHW LS means 
of SF (µg/L)1
NHB LS means 
of SF (µg/L) 2
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1. Least square means of serum ferritin (SF) were calculated for non-Hispanic white (NHW) subjects by using SUDAAN. 
2. Least square means of serum ferritin (SF) were calculated for non-Hispanic black (NHB) subjects by using SUDAAN. 
3. β coefficient corresponding to the change in serum ferritin concentrations (µg/L) between non-Hispanic black and non-
Hispanic white (reference group). 
4. Log transformation was used to correct highly right-skewed data distribution of serum protoporphyrin. 
5. β coefficient corresponding to the change in serum ferritin concentrations (µg/L) between married and non-married 
participants (reference group).  
6. β coefficient corresponding to the change in serum ferritin concentrations (µg/L) between participants with education 
level >12yr and ≤12 yr (reference group).  
7. Statistical significance is set at a p<0.05. Results were obtained by using SUDAAN regression analysis. 




Final regression models and revised model with serum ferritin concentration as dependent variable1.






β p β p β p
Age --- --- 1.3882 <0.0001* 1.4823 <0.0001*
Ethnicity 
 non-Hispanic white† 









































 >12 yr 
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%kcal from carbohydrate -1.1833 0.0039* -1.3162 0.0013* -0.7365 0.0391 
%kcal from fat -0.9011 0.0809 -1.2506 0.0091* -0.6607 0.1515 
calcium intake -0.0166 <0.0001* -0.0133 0.0013* -0.0114 0.0153 
serum total protein 45.5401 <0.0001* 50.3147 <0.0001* 36.6326 0.0007*
serum retinol 1.3217 0.0005* 1.0112 0.0141 1.1708 0.0121 
serum α-carotene -2.0959 0.0017* -2.5840 0.0013* -2.4820 0.0013*
serum β-cryptoxanthin -1.1107 0.1333 -0.9883 0.2099 -0.5355 0.4740 
serum lycopene -0.3281 0.3932 -0.1369 0.7221 0.2394 0.5702 
serum phosphorus -8.4969 0.1629 -2.1725 0.7177 2.5227 0.7016 
MCV 3.8530 0.0003* 4.2271 0.0001* 2.2118 0.0143 
TIBC -0.6895 <0.0001* -0.6765 <0.0001* -0.6047 <0.0001*
log-protoporphyrin 11.3513 0.4463 -14.3476 0.3964 -14.3616 0.4321 
GGT 0.6621 0.0004* 0.6014 0.0007* 1.7255 <0.0001*
CRP 6.3389 0.2953 1.6109 0.8309 1.5287 0.8417 
1. Results of final regression models obtained using SUDAAN regression analysis. Final model #1contained all 
significant variables from each sub-regression model. Final model #2 contained all variables in final model #1 with 
further adjustment for age, BMI, cigarette smoking and physical activity. 
2. Revised model was run based on final regression model #2 after excluding subjects with abnormal values of TIBC, 
serum total protein and GGT (normal TIBC: 240-450µg/dL, normal serum total protein: 6-8.5g/dL, normal GGT: <50 
(U/L). 
† Reference group. 
* Statistical significance is set at a p<0.01. 
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TABLE6 
Comparisons of least square means (LS means) of serum ferritin concentration among final regression and 
revised models. 
# Model n R2 NHW LS means 
of SF (µg/L)1
NHB LS means 
of SF (µg/L)2
Difference 
in SF (µg/L) 
p
Model 1 2648 0.1954 178.42 189.87 11.45 0.2131 
Model 2 2639 0.2271 178.77 190.10 11.33 0.1888 
Revised Model3 2090 0.1751 164.14 168.09 3.95 0.5886 
1. Least square means of serum ferritin (SF) were calculated for non-Hispanic white (NHW) subjects by using SUDAAN. 
2. Least square means of serum ferritin (SF) were calculated for non-Hispanic black (NHB) subjects by using SUDAAN. 
3. Revised model was run based on final regression model #2 after excluding subjects with abnormal values of TIBC, 




































Mean serum ferritin (ug/L)
non-Hispanic White non-Hispanic Black  Fig. 1    Geometric means of serum ferritin (µg/L) among NHANES III non-Hispanic white and non-Hispanic  













n mean SEM n mean SEM  
age (y) 235 55.9621 2.0883 164 50.7002 1.2359 0.0534 
Education (yr) 
 ≤12yr (%) 






















Poverty income ratio (PIR) 
 <1.3 (%) 
 1.3-3.5 (%) 





























Prevalence (%)        
 congestive heart failure 22 5.6943 2.1255 14 9.6592 3.3689 0.3555 
 diabetes mellitus 4 1.2063 0.6389 8 4.8673 1.9725 0.0606 
 heart attack 42 12.7124 2.8343 14 8.9879 2.7328 0.4045 
 hypertension 82 28.3035 4.5524 65 33.9806 3.3924 0.3595 
 stroke 26 6.3637 0.9380 14 6.1220 1.5049 0.9002 
BMI (kg/m2)
<18.5 (%) 
 18.5-25 (%) 
 25-30 (%) 




































waist circumference (cm) 190 100.7669 0.9919 147 99.3081 1.5467 0.4641 
Smoking status (%) 
 non smoker  
 former smoker  





























c-reactive protein (mg/dL) 235 2.2686 0.1462 164 2.1940 0.1243 0.7107 
serum albumin (g/dL) 232 3.9732 0.0490 163 3.8536 0.0317 0.0548 
WBC (103cells/mm3) 235 9.1721 0.1805 163 7.4799 0.1770 <0.0001*
platelet count (103cells/mm3) 235 281.6856 4.9016 163 282.0639 8.4728 0.9693 
plasma fibrinogen (mg/dL) 216 668.0087 11.4567 131 614.7575 11.2375 0.7441 
lymphocyte (103cells/mm3) 235 2.1838 0.0685 163 2.3668 0.0863 0.0954 
mononuclear (103cells/mm3) 233 0.5584 0.0129 160 0.4692 0.0156 0.0007*
hemoglobin (g/dL) 235 14.6319 0.1351 163 13.8277 0.1171 0.0006*
serum iron (µg/L) 234 62.0671 3.0403 164 61.1701 2.7020 0.8309 
serum ferritin (µg/L) 
 25-300 (%) 






















transferrin saturation (%) 234 19.6342 0.9648 164 19.8068 0.8975 0.8972 
TIBC 234 329.3691 4.5618 164 315.1581 5.0842 0.0625 
triglycerides (mg/dL) 233 162.3160 9.8269 164 141.8698 6.0820 0.1581 
total cholesterol (mg/dL) 235 198.5622 3.6845 164 206.5248 5.1076 0.2670 
HDL cholesterol (mg/dL) 232 41.9932 0.9229 164 47.6259 1.5877 0.0054*
LDL cholesterol (mg/dL) 89 122.6330 3.4264 72 144.1864 7.0443 0.0139*
Plasma glucose (mg/dL) 207 104.5986 2.3103 159 115.7463 5.4416 0.0770 
systolic blood pressure (mmHg) 206 130.2366 1.7616 158 133.0782 1.1767 0.1989 
diastolic blood pressure (mmHg) 206 76.6417 0.7133 158 78.3303 1.0381 0.1675 
1. The means of all continuous variables were compared between non-Hispanic white and non-Hispanic black male 
subjects using SUDAAN’s t-test. The frequencies of all categorical variables were compared between non-Hispanic 
white and non-Hispanic black male subjects using SUDAAN’s Chi-square test.  
* Statistical significance was set at a p<0.05 

































Fig. 2   The proportion of acute inflammation present subjects who had elevated serum ferritin concentration 
(>300µg/L), stratified by age and ethnicity. 
TABLE 8  
Risks of having elevated SF concentrations between NHW and NHB acute inflammation present NHANES III male 
subjects aged ≥20yrs. 1
# Model n non-Hispanic Black (NHB) 





2.153 (1.234  3.754) 
2.239 (1.333  3.760) 
1. Comparisons of adjusted odds ratios of having elevated serum ferritin (SF) concentrations in response to acute inflammation 
between non-Hispanic white (reference group) and non-Hispanic black male subjects. Elevated serum ferritin concentration 
defined as >300µg/L for male. 
2. Model 1 adjusted for age, ethnicity, PIR, education, BMI, smoking status, chronic diseases including cancer, congestive 
heart failure, heart attack, hypertension, diabetes and stroke. 
3. Model 2 further adjusted for cardiovascular risk factors including triglycerides, total cholesterol, HDL cholesterol, systolic 
and diastolic blood pressure in addition to the effects mentioned in footnote 2. 
 
TABLE 9 
Risk of having elevated SF concentrations per unit change in inflammation markers between NHW and NHB acute 
inflammation present NHANES III male subjects aged ≥20yrs.1
Model 12 Model 23
Inflammation Marker n β̂ (p)┼ n β̂ (p) ┼
c-reactive protein 366 0.0991(0.3556) 333 0.2070(0.0005)*
WBC 365 0.0558(<0.0001)* 332 0.0536(0.0001)*
serum albumin 364 0.0831(0.0201)* 331 0.0894(0.0031)*
lymphocyte count 365 0.1448(0.0040)* 332 0.1398(0.0038)*
monocyte count 361 0.3823(0.0987) 328 0.3183(0.1264) 
platelet count 365 0.0015(0.0002)* 332 0.0016(0.0003)*
1. Logistic regression models were used to estimate the magnitude of serum ferritin (SF) elevation associated with one 
unit change in inflammation markers.  
2. Model 1 adjusted for age, ethnicity, PIR, education, BMI, smoking status, chronic diseases including cancer, congestive 
heart failure, heart attack, hypertension, diabetes and stroke. 
3. Model 2 further adjusted for cardiovascular risk factors including triglycerides, total cholesterol, HDL cholesterol, 
systolic and diastolic blood pressure in addition to the effects mentioned in footnote 2. 
┼ P value corresponding to the comparisons between the β of non-Hispanic black and non-Hispanic white (reference  
 group), respectively. 











n mean SEM n mean SEM 
age (y) 62 38.8805 1.4053 92 40.4501 1.1217 
Education (yr) 
 ≤12yr (%) 



















Poverty income ratio (PIR) 
 <1.3 (%) 
 1.3-3.5 (%) 

























Prevalence (%)       
 cancer (various types) 0 0 0 0 0 0 
 congestive heart failure 2 2.0423 0.5390 2 3.5661 2.3752 
 diabetes mellitus 0 0 0 0 0 0 
 heart attack 9 6.7880 3.6203 2 2.7044 2.1657 
 hypertension 11 6.8267 1.6187 21 18.6453 3.7319 
 stroke 2 1.7920 0.1412 2 0.9648 0.7055 
 abnormal liver enzymes‡ 21 35.6880 4.8662 50 59.8186 5.1176 
BMI (kg/m2)
<18.5 (%) 
 18.5-25 (%) 
 25-30 (%) 































alcohol consumption (drinks/mo)† 
 non-drinker (%) 
 light drinker (%) 
 moderate drinker (%) 































c-reactive protein (mg/dL) 62 0.2542 0.0089 92 0.5426 0.1086 
WBC (103cells/mm3) 60 7.8289 0.2276 90 6.3984 0.2275 
platelet count (103cells/mm3) 60 246.6482 10.3299 90 237.3385 9.6898 
serum albumin (g/dL) 62 4.2899 0.0321 90 4.0293 0.0457 
hemoglobin (g/dL) 60 15.3430 0.2034 90 14.4465 0.1816 
serum iron (µg/L) 62 97.8023 5.4525 92 112.6925 5.8364 
serum ferritin (µg/L) 
 <25 (%) 
 25-300 (%) 

























transferrin saturation (%) 62 27.6997 1.6530 91 32.4767 2.0632 
TIBC 62 357.7358 4.7743 91 353.8499 8.1383 
AST SI(U/L) 62 33.8477 2.1921 90 54.9738 5.8770 
ALT SI (U/L) 62 35.9374 3.1056 90 46.3029 3.3367 
ALP SI(U/L) 62 85.5920 2.7759 90 90.2533 3.2261 
GGT SI(U/L) 49 69.4828 9.2045 74 127.0551 29.8752 
LDH SI(U/L) 62 167.8463 5.5962 89 174.1724 3.0130 
serum total bilirubin (mg/dL) 62 0.6407 0.0313 90 0.6953 0.0277 
‡ Serum aspartate or alanine aminotransferase above 40U/L. 
† Alcohol consumption was further divided into 4 categories: non-drinker (0 drink/mo), light drinker (1-30 drinks/mo), moderate  
































non-Hispanic w hite non-Hispanic black  
Fig. 3   Distribution of hepatitis C genotypes between non-Hispanic white and non-Hispanic black NHANES III 
male subjects aged ≥20. 
TABLE 11 
Distribution of hepatitis C genotypes between non-Hispanic white  
and non-Hispanic black NHANES III male participants aged ≥20.
non-Hispanic white non-Hispanic black hepatitis C 
genotypes n % n % 
1 19 60.15 43 57.58
2 7 11.94 26 30.60
3 1 1.18 2 3.65
4 7 18.87 3 2.56
5 2 7.85 0 0
6 0 0 3 5.60
TABLE 12  
Risk of having elevated SF concentrations between NHW and NHB  
hepatitis C infected NHANES III male participants aged ≥20. 1
# Model n non-Hispanic Black (NHB) 





1.626 (0.682  3.877) 
1.910 (0.765  4.768) 
1. Comparisons of adjusted odds ratios of having elevated serum ferritin (SF) concentrations in response to hepatitis C between 
non-Hispanic white (reference group) and non-Hispanic black male subjects. Elevated serum ferritin concentration defined 
as >300µg/L for male. 
2. Model 1 adjusted for age, ethnicity, PIR, BMI, C-reactive protein and alcohol consumption. 
3. Model 2 further adjusted for serological markers including AST, ALT, ALP, LDH and serum total bilirubin in addition to 





Risk of having elevated SF concentrations per unit change in serological markers between NHW and 
NHB hepatitis C infected NHANES III male subjects aged ≥20 yrs.1
Inflammation Marker Model 12 Model 23
n β̂ (p)┼ n β̂ (p) ┼
aspartate aminotransferase (AST) 146 0.00301(0.4012) 145 0.00519(0.3412) 
alanine aminotransferase (ALT) 146 0.0013(0.7363) 145 0.00158(0.6859) 
alkaline phosphatase (ALP) 146 0.00388(0.0595) 145 0.00452(0.0435)*
lactate dehydrogenase (LDH) 145 0.00201(0.0892) 145 0.00159(0.02120) 
serum total bilirubin 146 0.3681(0.2276) 145 0.4032(0.2578) 
1. Logistic regression models were used to estimate the magnitude of serum ferritin (SF) elevation associated with one 
unit change in serological markers.  
2. Model 1 adjusted for age, ethnicity, education, PIR, BMI, C-reactive protein and alcohol consumption. 
3. Model 2 further adjusted for other serological markers including AST, ALT, ALP, LDH and serum total bilirubin in 
addition to the effects mentioned in footnote 2. 
┼ P value corresponding to the comparisons between the β of non-Hispanic black and non-Hispanic white (reference  
 group), respectively. 
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